uniQure (QURE) 10-K25 Feb 222021 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2021	Feb. 23, 2022	Jun. 30, 2021
Document and Entity Information
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-36294
Entity Registrant Name	uniQure N.V.
Entity Incorporation, State or Country Code	P7
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	Paasheuvelweg 25
Entity Address, City or Town	Amsterdam
Entity Address, Country	NL
Entity Address, Postal Zip Code	1105 BP
City Area Code	31
Local Phone Number	20-240-6000
Title of 12(b) Security	Ordinary shares, par value €0.05 per share
Trading Symbol	QURE
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	true
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 1,418.3
Entity Common Stock, Shares Outstanding		46,456,984
Auditor Name	KPMG Accountants N.V.
Auditor Firm ID	1012
Auditor Location	Amstelveen, The Netherlands
Entity Central Index Key	0001590560
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 556,256	$ 244,932
Accounts receivable and contract asset	58,768	6,618
Prepaid expenses	10,540	4,337
Other current assets and receivables	2,675	3,024
Total current assets	628,239	258,911
Non-current assets
Property, plant and equipment, net	43,505	32,328
Operating lease right-of-use assets	25,573	26,086
Intangible assets, net	62,686	3,361
Goodwill	27,633	542
Deferred tax assets, net	15,647	16,419
Other non-current assets	5,897	2,748
Total non-current assets	180,941	81,484
Total assets	809,180	340,395
Current liabilities
Accounts payable	2,502	3,772
Accrued expenses and other current liabilities	28,487	18,038
Current portion of operating lease liabilities	5,774	5,524
Total current liabilities	36,763	27,334
Non-current liabilities
Long-term debt	100,963	35,617
Operating lease liabilities, net of current portion	28,987	30,403
Contingent consideration	29,542
Deferred tax liability, net	12,913
Other non-current liabilities	4,236	3,136
Total non-current liabilities	176,641	69,156
Total liabilities	213,404	96,490
Commitments and contingencies
Shareholders' equity
Ordinary shares, 0.05 par value: 80,000,000 shares authorized as of December 31, 2021 and 60,000,000 shares authorized as of December 31, 2020 and 46,298,635 and 44,777,799 ordinary shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively	2,802	2,711
Additional paid-in-capital	1,076,972	1,016,018
Accumulated other comprehensive (loss) / income	(28,856)	9,907
Accumulated deficit	(455,142)	(784,731)
Total shareholders' equity	595,776	243,905
Total liabilities and shareholders' equity	$ 809,180	$ 340,395

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - € / shares	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED BALANCE SHEETS
Ordinary shares, par value (in euros per share)	€ 0.05	€ 0.05
Ordinary shares, authorized	80,000,000	60,000,000
Ordinary shares, issued	46,298,635	44,777,799
Ordinary shares, outstanding	46,298,635	44,777,799

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Total revenues	$ 524,002	$ 37,514	$ 7,281
Operating expenses:
Cost of contract revenues	(24,976)
Research and development expenses	(143,548)	(122,400)	(94,737)
Selling, general and administrative expenses	(56,290)	(42,580)	(33,544)
Total operating expenses	(224,814)	(164,980)	(128,281)
Other income	12,306	3,342	1,888
Other expense	(876)	(1,302)	(2,028)
Income / (loss) from operations	310,618	(125,426)	(121,140)
Interest income	162	938	3,547
Interest expense	(7,474)	(3,825)	(3,810)
Foreign currency gains / (losses), net	29,660	(13,613)	(268)
Other non-operating (losses) / gains, net	(160)	483	(2,530)
Income / (loss) before income tax (expense) / benefit	332,806	(141,443)	(124,201)
Income tax (expense) / benefit	(3,217)	16,419
Net income / (loss)	329,589	(125,024)	(124,201)
Other comprehensive (loss) / gain:
Foreign currency translation adjustments	(38,763)	16,596	570
Total comprehensive gain / (loss)	$ 290,826	$ (108,428)	$ (123,631)
Earnings per ordinary share - basic
Basic net income / (loss) per ordinary share	$ 7.17	$ (2.81)	$ (3.11)
Earnings per ordinary share - diluted
Diluted net income / (loss) per ordinary share	$ 7.04	$ (2.81)	$ (3.11)
Weighted average shares - basic	45,986,467	44,466,365	39,999,450
Weighted average shares - diluted	46,840,972	44,466,365	39,999,450
License revenues
Total revenues	$ 517,400	$ 4,352
License revenues from related party
Total revenues	0	32,967	$ 4,988
Collaboration revenues
Total revenues	$ 6,602	59
Collaboration revenues from related party
Total revenues		$ 136	$ 2,293

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Ordinary shares	Additional paid-in capital	Accumulated other comprehensive (loss)	Accumulated deficit	Total
Beginning balance at Dec. 31, 2018	$ 2,299	$ 720,072	$ (7,259)	$ (535,506)	$ 179,606
Beginning balance (in shares) at Dec. 31, 2018	37,351,653
Increase (decrease) in shareholders' equity
Income (Loss) for the period				(124,201)	(124,201)
Other comprehensive Income (loss)			570		570
Issuance of ordinary shares	$ 311	242,363			242,674
Issuance of ordinary shares (in shares)	5,625,000
Exercise of share options	$ 25	5,210			5,235
Exercise of share options (in shares)	453,232
Restricted and performance share units distributed during the period	$ 14	(14)
Restricted and performance share units distributed during the period (in shares)	235,692
Share-based compensation expense		17,533			17,533
Issuance of ordinary shares relating to employee stock purchase plan		368			368
Issuance of ordinary shares relating to employee stock purchase plan (in shares)	9,202
Hercules warrants exercise	$ 2	1,271			1,273
Hercules warrants exercise (in shares)	37,175
Ending balance at Dec. 31, 2019	$ 2,651	986,803	(6,689)	(659,707)	323,058
Ending balance (in shares) at Dec. 31, 2019	43,711,954
Increase (decrease) in shareholders' equity
Income (Loss) for the period				(125,024)	(125,024)
Other comprehensive Income (loss)			16,596		16,596
Exercise of share options	$ 29	7,169			7,198
Exercise of share options (in shares)	498,678
Restricted and performance share units distributed during the period	$ 31	(31)
Restricted and performance share units distributed during the period (in shares)	560,986
Share-based compensation expense		21,831			21,831
Issuance of ordinary shares relating to employee stock purchase plan		246			246
Issuance of ordinary shares relating to employee stock purchase plan (in shares)	6,181
Ending balance at Dec. 31, 2020	$ 2,711	1,016,018	9,907	(784,731)	$ 243,905
Ending balance (in shares) at Dec. 31, 2020	44,777,799				44,777,799
Increase (decrease) in shareholders' equity
Income (Loss) for the period				329,589	$ 329,589
Other comprehensive Income (loss)			(38,763)		(38,763)
Issuance of ordinary shares	$ 55	29,509			29,564
Issuance of ordinary shares (in shares)	921,730
Income tax benefit of past share issuance cost		3,047			3,047
Exercise of share options	$ 15	2,638			2,653
Exercise of share options (in shares)	241,496
Restricted and performance share units distributed during the period	$ 21	(21)
Restricted and performance share units distributed during the period (in shares)	352,886
Share-based compensation expense		25,635			25,635
Issuance of ordinary shares relating to employee stock purchase plan		146			146
Issuance of ordinary shares relating to employee stock purchase plan (in shares)	4,724
Ending balance at Dec. 31, 2021	$ 2,802	$ 1,076,972	$ (28,856)	$ (455,142)	$ 595,776
Ending balance (in shares) at Dec. 31, 2021	46,298,635				46,298,635

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net income / (loss)	$ 329,589	$ (125,024)	$ (124,201)
Adjustments to reconcile net income / (loss) to net cash generated from / (used in) operating activities:
Depreciation and amortization expense	7,299	10,648	6,669
Share-based compensation expense	25,635	21,831	17,533
Deferred tax expense / (income)	3,210	(16,419)
Changes in fair value of contingent consideration and derivative financial instruments	6,843	(483)	2,530
Unrealized foreign exchange (gains) / losses, net	(31,335)	14,730	891
Change in deferred revenue		(33,642)	(4,999)
Other non-cash items, net	(2,800)
Changes in operating assets and liabilities:
Contract asset related to CSL Behring milestone payments	(55,000)
Accounts receivable, prepaid expenses, and other current assets and receivables	(3,959)	(6,967)	(4,769)
Accounts payable	(727)	(2,701)	1,652
Accrued expenses, other liabilities, and operating leases	9,204	3,199	6,010
Net cash generated from / (used in) operating activities	287,959	(134,828)	(98,684)
Cash flows from investing activities
Acquisition of Corlieve, net of cash acquired	(49,949)
Purchases of intangible assets		(2,213)	(996)
Purchases of property, plant, and equipment	(17,438)	(7,271)	(5,651)
Net cash used in investing activities	(67,387)	(9,484)	(6,647)
Cash flows from financing activities
Proceeds from loan increment, net of debt issuance costs	64,067
Proceeds from public offering of shares, net of issuance costs			242,718
Proceeds from issuance of ordinary shares	30,899
Proceeds from issuance of ordinary shares related to employee stock option and purchase plans	2,798	7,444	5,603
Repayment of debt acquired through acquisition of Corlieve	(1,572)
Share issuance costs from issuance of ordinary shares	(1,334)
Proceeds from exercise of warrants			500
Net cash generated from financing activities	94,858	7,444	248,821
Currency effect on cash, cash equivalents and restricted cash	(3,757)	3,822	(106)
Net increase / (decrease) in cash, cash equivalents and restricted cash	311,673	(133,046)	143,384
Cash, cash equivalents and restricted cash at beginning of period	247,680	380,726	237,342
Cash, cash equivalents and restricted cash at the end of period	559,353	247,680	380,726
Cash and cash equivalents	556,256	244,932	377,793
Restricted cash related to leasehold and other deposits	3,097	2,748	2,933
Total cash, cash equivalents and restricted cash	559,353	247,680	380,726
Supplemental cash flow disclosures:
Cash paid for interest	(6,539)	(4,131)	(3,117)
Non-cash increase in accounts payables and accrued expenses and other current liabilities related to purchases of property, plant, and equipment	$ 1,488	$ 630	$ 313

General business information

General business information	12 Months Ended
General business information	Dec. 31, 2021
General business information
General business information	1. uniQure (the “Company”) was incorporated on January 9, 2012 as a private company with limited liability ( besloten vennootschap met beperkte aansprakelijkheid naamloze vennootschap The Company is registered in the trade register of the Dutch Chamber of Commerce ( Kamer van Koophandel The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
Summary of significant accounting policies	Dec. 31, 2021
Summary of significant accounting policies
Summary of significant accounting policies	2. 2.1 Basis of preparation The Company prepared its consolidated financial statements in compliance with generally accepted accounting principles in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The consolidated financial statements have been prepared under the historical cost convention, except for derivative financial instruments and contingent consideration, which are recorded at fair value through profit or loss. The consolidated financial statements are presented in U.S. dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parenthesis, converted at the foreign exchange rate as of the transaction date. The consolidated financial statements presented have been prepared on a going concern basis based on the Company’s cash and cash equivalents as of December 31, 2021 and the Company’s budgeted cash flows for the twelve months following the issuance date. 2.2 The preparation of consolidated financial statements, in conformity with U.S. GAAP and Securities and Exchange Commission (“SEC”) rules and regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to the treatment of the share and purchase agreement (“SPA”) entered into on June 21, 2021 to acquire all of the outstanding ordinary shares of Corlieve Therapeutics SAS (“Corlieve”), a privately held French gene therapy company (“Corlieve Transaction”), the treatment of the commercialization and license agreement entered into (“CSL Behring Agreement”) between the Company and CSL Behring LLC (“CSL Behring”), the assessment of a valuation allowance on the Company’s deferred tax assets in the Netherlands and the U.S., and the December 1, 2020, amendment (“amended BMS CLA”) of the 2015 collaboration and license agreement (“BMS CLA”) between the Company and Bristol-Myers Squibb (“BMS”). If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate. 2.3 The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. 2.3.1 The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. Subsidiaries are all entities over which the Company has a controlling financial interest either through variable interest or through voting interest. Currently, the Company has no involvement with variable interest entities. Inter-company transactions, balances, income, and expenses on transactions between uniQure entities are eliminated in consolidation. Profits and losses resulting from inter-company transactions that are recognized in assets are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. 2.3.2 The Company presents assets and liabilities in the consolidated balance sheets based on current and non-current classification. The term current assets is used to designate cash and other assets, or resources commonly identified as those that are reasonably expected to be realized in cash or sold or consumed during the normal operating cycle of the business. The Company’s normal operating cycle is twelve months. All other assets are classified as non-current. The term current liabilities is used principally to designate obligations whose liquidation is reasonably expected to require the use of existing resources properly classifiable as current assets, or the creation of other current liabilities. Current liabilities are expected to be settled in the normal operating cycle. The Company classifies all other liabilities as non-current. Deferred tax assets and liabilities are classified as non-current assets and liabilities, if any. 2.3.3 The functional currency of the Company and each of its entities (except for uniQure Inc. and Corlieve AG) is the euro (€). This represents the currency of the primary economic environment in which the entities operate. The functional currency of uniQure Inc. is the U.S. dollar ($) and the functional currency of Corlieve AG is the Swiss Franc. The consolidated financial statements are presented in U.S. dollars. Foreign currency transactions are measured and recorded in the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies at exchange rates prevailing at balance sheet date are recognized in profit and loss. Upon consolidation, the assets and liabilities of foreign operations are translated into the functional currency of the shareholding entity at the exchange rates prevailing at the balance sheet date; items of income and expense are translated at monthly average exchange rates. The consolidated assets and liabilities are translated from uniQure N.V.’s functional currency, euro, into the reporting currency U.S. dollar at the exchange rates prevailing at the balance sheet date; items of income and expense are translated at monthly average exchange rates. Issued capital and additional paid-in capital are translated at historical rates with differences to the balance sheet date rate recorded as translation adjustments in other comprehensive income / loss. The exchange differences arising on translation for consolidation are recognized in “accumulated other comprehensive income / loss”. On disposal of a foreign operation, the component of other comprehensive income / loss relating to that foreign operation is recognized in profit or loss. 2.3.4 The Company measures certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. ASC 820, Fair Value Measurements and Disclosures ● Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities in markets that are not active or models for which the inputs are observable, either directly or indirectly. ● Level 3 - Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and are unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Items measured at fair value on a recurring basis include financial instruments and contingent consideration (Note 5, “ Fair value measurement 2.3.5 Corlieve transaction On July 30, 2021 (“Acquisition Date”), the Company acquired Corlieve. The Company evaluated the Corlieve transaction as to whether or not the transaction should be accounted for as a business combination or asset acquisition. Refer to Note 3 “ Corlieve transaction a. Goodwill Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the net assets assumed in a business combination. Goodwill is not amortized but is evaluated for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would more likely than not reduce the fair value of the reporting unit below its carrying amount. As of December 31, 2021, the Company has not recognized any impairment charges related to goodwill. Refer to Note 3 “ Corlieve transaction b. Acquired research and development The Company identified various licenses that combined with the results of the research and development activities conducted in relation to AMT-260 since incorporation of Corlieve in 2019 constitute an In-process research and development intangible asset (“IPR&D Intangible Asset”). The IPR&D Intangible Asset is considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and is not amortized. If and when development is completed, which generally occurs when regulatory approval to market a product is obtained, the associated asset would be deemed finite-lived and would then be amortized based on its respective useful life at that point in time. As of December 31, 2021, the Company has not recognized any impairment charges related to the IPR&D Intangible Asset. In case of abandonment, the IPR&D Intangible Asset will be written-off. In accordance with ASC 350, Intangibles – Goodwill and Other, the Company tests indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair value of the IPR&D Intangible Asset is below its carrying amount. Refer to Note 3 “ Corlieve transaction c. Contingent consideration Each reporting period, the Company revalues the contingent consideration obligations associated with the Corlieve transaction to their fair value and records changes in the fair value within research and development expenses. Changes in contingent consideration result from changes in assumptions regarding the probabilities of achieving the relevant milestones, or probability of success (“POS”), the estimated timing of achieving such milestones, and the interest rate to discount the payments. Payments made soon after the acquisition date are recorded as cash flows from financing activities, and payments, or the portion of the payments, not made soon after the acquisition date are recorded as cash flows from operating activities. Refer to Note 3 “ Corlieve transaction 2.3.6 The consolidated statements of cash flows have been prepared using the indirect method. The cash disclosed in the consolidated statements of cash flows is comprised of cash and cash equivalents. Cash and cash equivalents include bank balances, demand deposits and other short-term highly liquid investments (with maturities of less than three months at the time of purchase) that are readily convertible into a known amount of cash and are subject to an insignificant risk of fluctuation in value. Cash flows denominated in foreign currencies have been translated at the average exchange rates. Exchange differences, if any, affecting cash and cash equivalents are shown separately in the consolidated statements of cash flows. Interest paid and received, and income taxes are included in net cash (used in) provided by operating activities. 2.3.7 Operating segments are identified as a component of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment, which comprises the discovery, development, and commercialization of innovative gene therapies. 2.3.8 The Company follows the provisions of ASC 260, Earnings Per Share Diluted net income / (loss) per share reflects the dilution that would occur if share options or warrants to issue ordinary shares were exercised, performance or restricted share units were distributed, or shares under the employee share purchase plan were issued. However, potential ordinary shares are excluded if their effect is anti-dilutive. Refer to Note 16 “ Basic and diluted earnings per share 2.3.9 Long-lived assets, which include property, plant, and equipment and finite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. Right-of-use assets are also reviewed for impairment in accordance with ASC 360, Property, Plant, and Equipment Refer to Note 2.3.5 “ Corlieve transaction 2.3.10 Property, plant, and equipment is comprised mainly of laboratory equipment, leasehold improvements, construction-in-progress (“CIP”) and office equipment. All property, plant and equipment is stated at cost less accumulated depreciation. CIP consists of capitalized expenses associated with construction of assets not yet placed into service. Depreciation commences on CIP once the asset is placed into service based on its useful life determined at that time. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss on the transaction is recognized in the consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets (or in the case of leasehold improvements a shorter lease term), which are as follows: · Between 10 – 15 years · 5 years · Between 3 – 5 years 2.3.11 The Company adopted ASC 842, Leases The Company measured lease liabilities at the present value of the future lease payments as of January 1, 2019. The Company used an incremental borrowing rate to discount the lease payments. The Company derived the discount rate, adjusted for differences such as in the term and payment patterns, from the Company’s loan from Hercules Technology Growth Capital, Inc (“Hercules Capital”), which was refinanced immediately prior to the January 1, 2019 adoption date in December 2018. The right-of-use asset is valued at the amount of the lease liability reduced by the remaining December 31, 2018 balance of lease incentives received. The lease liability is subsequently measured at the present value of the future lease payments as of the reporting date with a corresponding adjustment to the right-to-use asset. Absent a lease modification, the Company will continue to utilize the January 1, 2019, incremental borrowing rate. For leases recognized after the adoption date, the Company determines if an arrangement is a lease at inception. Operating lease right-of-use assets and lease liabilities are initially recognized based on the present value of future minimum lease payments over the lease term at commencement date calculated using an incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily available. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of twelve months or less are not recognized on the consolidated balance sheets. 2.3.12 Deposits paid are either presented as other current assets or as other non-current assets based on duration of the underlying contractual arrangement. Deposits are classified as restricted cash and primarily relate to facility leases. Contract assets are presented in other current assets or as other non-current assets based on the timing of the right to consideration. 2.3.13 Prepaid expenses are amounts paid in the period, for which the benefit has not been realized, and include payments made for insurance and research and clinical contracts. The related expense will be recognized in the subsequent period as incurred. 2.3.14 2.3.15 Accounts payables are invoiced amounts related to obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payables are recognized at the amounts invoiced by suppliers. Accrued expenses are recognized for goods or services that have been acquired in the ordinary course of business. Contract liabilities are presented in accounts payable and accrued expenses. 2.3.16 Long-term debt is initially recognized at cost and presented net of original issue discount or premium and debt issuance costs on the consolidated balance sheets. Amortization of debt discount and debt issuance costs is recognized as interest expense in profit and loss over the period of the debt, using the effective interest rate method. 2.3.17 Pensions and other post-retirement benefit plans The Company has a defined contribution pension plan for all employees at its Amsterdam facility in the Netherlands, which is funded by the Company through payments to an insurance company, with individual accounts for each participants’ assets. The Company has no legal or constructive obligation to pay further contributions if the plan does not hold sufficient assets to pay all employees the benefits relating to services rendered in the current and prior periods. The contributions are expensed as incurred. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. In 2016, the Company adopted a qualified 401(k) Plan for all employees located in the United States. The 401(k) Plan offers both a pre-tax and post-tax (Roth) component. Employees may contribute up to the IRS statutory limit each calendar year. The Company matches $0.50 for every $1.00 contributed to the plan by participants up to 6% of base compensation. Employer contributions are recognized as they are contributed, as long as the employee is rendering services in that period. If employer contributions are made in periods after an individual retires or terminates, the estimated cost is accrued during the employee’s service period. 2.3.18 The Company accounts for its share-based compensation awards in accordance with ASC 718, Compensation-Stock Compensation. All the Company’s share-based compensation plans for employees are equity-classified. ASC 718 requires all share-based compensation to employees, including grants of employee options, restricted share units, performance share units and modifications to existing instruments, to be recognized in the consolidated statements of operations and comprehensive loss based on their grant-date fair values, net of an estimated forfeiture rate, over the requisite service period. Forfeitures of employee options are recognized as they occur. Compensation expense related to Performance Share Units is recognized when the Company considers achievement of the milestones to be probable. The requirements of ASC 718 are also applied to nonemployee share-based payment transactions except for specific guidance on certain inputs to an option-pricing model and the attribution of cost. The Company uses a Hull & White option model to determine the fair value of option awards. The model captures early exercises by assuming that the likelihood of exercises will increase when the share-price reaches defined multiples of the strike price. This analysis is performed over the full contractual term. 2.3.19 Revenue recognition The Company primarily generates revenue from its commercialization and license agreement with CSL Behring and its collaboration, research, and license agreements with BMS for the development and commercialization of product candidates. CSL Behring collaboration On June 24, 2021 (“Signing Date”), the Company entered into a commercialization and license agreement pursuant to which CSL Behring received exclusive global rights to etranacogene dezaparvovec (“Product”). The Company concluded that CSL Behring is a customer in accordance with ASC 606, Revenue from Contracts with Customers (i) Sale of the exclusive global rights to the Product (“License Sale”); and (ii) Generate information to support the regulatory approval of the current and next generation manufacturing process of Product and to provide any such information generated to CSL Behring (“Manufacturing Development”). These performance obligations are considered distinct from one another, as CSL Behring can benefit from the identified service either on its own or together with other resources that are readily available to CSL Behring, and as the performance obligations are separately identifiable from other performance obligations in the CSL Behring Agreement. Refer to Note 4 “ Collaboration arrangements and concentration of credit risk Bristol-Myers Squib collaboration The Company initially entered into collaboration, research, and license agreements with BMS in 2015 and amended them in 2020. The Company evaluated the initial BMS CLA and determined that its performance obligations were as follows: ● Providing pre-clinical research activities (“Collaboration Revenue”); ● Providing clinical and commercial manufacturing services for products (“Manufacturing Revenue”); and ● Providing access to its technology and know-how in the field of gene therapy as well as actively contributing to the target selection, the collaboration as a whole, the development during the target selection, the pre-clinical and the clinical phase through participating in joint steering committee and other governing bodies (“License Revenue”). As further discussed in Note 4, “ Collaboration arrangements and concentration of credit risk License Revenue Until the December 2020 amendment of the BMS CLA the Company recognized License Revenue over the expected performance period based on its measure of progress towards the completion of certain activities related to its services. Following the December 2020 amendment of the BMS CLA the Company’s performance was materially completed and it had satisfied its performance obligation (see Note 4, “Collaboration arrangements and concentration of credit risk” Collaboration and Manufacturing Revenue The Company recognizes Collaboration Revenues associated with optional work orders it receives from BMS to provide analytical development and process development activities that are reimbursable by BMS in accordance with the BMS CLA as well as the amended BMS CLA. BMS and the Company entered into a Master Clinical Supply Agreement in April 2017 for the Company to supply gene therapy products during the clinical phase as well as into a binding term sheet to supply gene therapy products during the commercial phase to BMS. In December 2020, BMS and the Company also entered into a Research Supply Agreement. Revenues from product sales will be recognized when earned. The Company will provide these services as it receives optional work orders from BMS in relation to such services. 2.3.20 The Company receives certain government and regional grants, which support its research efforts in defined projects, and include contributions towards the cost of research and development. These grants generally provide for reimbursement of approved costs incurred as defined in the respective grants and are deferred and recognized in the statements of operations and comprehensive loss over the period necessary to match them with the costs they are intended to compensate, when it is probable that the Company has complied with any conditions attached to the grant and will receive the reimbursement. The Company’s other income also consists of employee retention credits received under the U.S. Coronavirus Aid, Relief, and Economic Security Act, income related to a settlement agreement that the Company and VectorY B.V. entered into in April 2021, as well as income from subleasing part of the Company’s Amsterdam facility. Other expense consists of expenses incurred in relation to the subleasing income. 2.3.21 Research and development costs are expensed as incurred. Research and development expenses generally consist of laboratory research, clinical trials, statistical analysis, and report writing, regulatory compliance costs incurred with clinical research organizations and other third-party vendors (including post-approval commitments to conduct consistency and comparability studies). In addition, research and development expenses consist of start-up and validation costs related to the Company’s Lexington facility and the development and improvement of the Company’s manufacturing processes and methods. Furthermore, research and development costs include costs of materials and costs of intangible assets purchased from others for use in research and development activities. The costs of intangibles that are purchased from others for a particular research and development project and that have no alternative future uses (in other research and development projects or otherwise) are expensed as research and development costs at the time the costs are incurred or at the time when no alternative future use is identified. 2.3.22 Income taxes are recorded in accordance with ASC 740, Income Taxes The benefits of tax positions are recognized only if those positions are more likely than not, based on the technical merits, to be sustained upon examination. Recognized tax positions are measured at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. The determination as to whether the tax benefit will more-likely-than-not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December 31, 2021, and 2020, the Company did not have any significant unrecognized tax benefits. 2.3.23 Recently Adopted Accounting Pronouncements Recent Accounting Pronouncements Not Yet Effective ASU 2021-10: Government Assistance In November 2018, the FASB issued ASU 2021-10, Government Assistance (Topic 832) which discusses the requirements for disclosures related to transactions with a government. ASU 2021-10 is effective for fiscal years beginning after December 15, 2021. The new disclosure requirements will require disclosures around 1) information about the nature of the transactions and the related accounting policy used to account for the transactions, 2) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, and 3) significant terms and conditions of the transactions, including commitments and contingencies. An entity should apply the updates prospectively or retrospectively. The Company currently includes information on government grants and does not expect these amendments to have a material impact on the Company’s consolidated financial statements.

Corlieve transaction

Corlieve transaction	12 Months Ended
Corlieve transaction	Dec. 31, 2021
Corlieve transaction
Corlieve transaction	3. Corlieve transaction At the Acquisition Date, the Company acquired Corlieve. Following Corlieve’s formation in November 2019, Corlieve obtained exclusive licenses to certain patents from two French research institutions that continue to collaborate with the Company. Corlieve also obtained an exclusive license from Regenxbio Inc. (“Regenxbio”) to use AAV9 to deliver any sequence that affects the expression of the Glutamate inotropic receptor kainate type subunit 2 (“GRIK 2”) gene sequence in humans. Corlieve and Regenxbio simultaneously entered into a collaboration plan related to agreed joint preclinical research and development activities. At the Acquisition Date, Corlieve and its Swiss subsidiary, Corlieve Therapeutics AG, employed seven employees. Corlieve’s result for the full year 2021 was a $7.3 million loss. The result included in the Company’s consolidated results for the year ended December 31, 2021 is a $4.1 million loss. The Company evaluated the Corlieve transaction as to whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. Based on the fair values of the gross assets acquired, the Company determined the screen test was not met. The Company further analyzed whether or not the acquired inputs and processes that have the ability to create outputs would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. Identifiable assets and liabilities of Corlieve, including identifiable intangible assets, were recorded at their fair values as of the Acquisition Date, when the Company obtained control. The excess of the fair value of the consideration transferred over the fair value of the net assets acquired was recorded as goodwill. The following table summarizes the fair values assigned to assets acquired and the liabilities assumed by the Company, along with the resulting goodwill, as of the Acquisition Date: Allocation € (in thousands) Consideration Cash € 44,876 Contingent consideration 20,165 Liability related to Mandatorily Redeemable Shares (see below) 719 Fair value of total consideration € 65,760 Recognized amounts of identifiable assets acquired and liabilities assumed Current assets including € € 2,902 Property, plant and equipment 34 Identifiable intangible asset 53,564 Current liabilities (1,132) Deferred tax liability, net (11,915) Debt (1,352) Other non-current liabilities (260) Fair value of net assets acquired 41,841 Goodwill 23,919 € 65,760 Consideration On the Acquisition Date, the Company acquired 97.7% of the outstanding ordinary shares of Corlieve in return for EUR 44.9 million ($53.3 million as of the Acquisition Date). As is contractually required the Company acquired the remaining outstanding ordinary shares on February 9, 2022 following the expiration of a minimum holding period. The Company recorded a liability related to these Mandatorily Redeemable Shares for an amount of EUR 0.7 million ($0.9 million) as of the Acquisition Date. The Company financed the Corlieve Transaction from its cash on hand. In addition to the payments to acquire 100% of the outstanding ordinary shares, Corlieve’s former shareholders are eligible to receive up to EUR 35.8 million ($40.6 million as of December 31, 2021) upon achievement of certain development milestones through Phase I/II and EUR 143.1 million ($162.3 million as of December 31, 2021) upon achievement of certain milestones associated with Phase III development and obtaining approval to commercialize Corlieve’s target candidate for the treatment of temporal lobe epilepsy (“AMT-260” or “TLE”) in the United States of America and the European Union. The Company may elect to pay up to 25% of such milestone payments through the issuance of the Company’s ordinary shares. As of the Acquisition Date, the Company recorded EUR 20.2 million ($24.0 million) as a contingent liability (presented as “Non-current liability”) for the fair value of these milestone payments. The fair value of the contingent liability as of December 31, 2021 amounted to EUR 26.0 million ($29.5 million). Changes in fair value of the contingent liability are recognized within research and development expenses in the consolidated statements of operations. Identified intangible assets The Company identified various licenses that combined with the results of the research and development activities conducted in relation to AMT-260 since incorporation of Corlieve in 2019 constitute an In-process research and development intangible asset (“IPR&D Intangible Asset”). The Company determined the fair value of the IPR&D Intangible Asset using a present value model based on expected cash flows. Estimating the amounts and timing of cash flows required to complete the development of AMT-260 as well as net sales, cost of goods sold, and sales and marketing costs involved considerable judgment and uncertainty. The expected cash flows are materially impacted by the probability of successfully completing the various stages of development (i.e., dosing of first patient in clinical trial, advancing into late-stage clinical development and obtaining approval to commercialize a product candidate) as well as the weighted average cost of capital of 10.4% used to discount the expected cash flows. Based on all such information and its judgment the Company estimated the fair value of the IPR&D Intangible Asset at EUR 53.6 million ($63.6 million) as of the Acquisition Date. Deferred tax liability, net Corlieve’s deferred tax assets at the time of acquisition amounted to EUR 1.5 million ($1.7 million). Recognition of the IPR&D Intangible Asset gave rise to a deferred tax liability of EUR 13.4 million ($15.9 million) at the enacted French corporate income tax rate of 25.0%. The Company consequently recorded a net deferred tax liability of EUR 11.9 million ($14.2 million as of the Acquisition Date). Changes in the net deferred tax liability after the Acquisition Date will be recorded in income tax expense in the consolidated statements of operations. Goodwill Goodwill represents the excess of total consideration over the estimated fair value of net assets acquired. The Company recorded EUR 23.9 million ($28.4 million) of goodwill in the consolidated balance sheet as of the Acquisition Date. The goodwill primarily relates to the recognition of a deferred tax liability recognized in association with the IPR&D Intangible asset of EUR 13.4 million ($15.9 million as of Acquisition Date) as well as the fair market value of the experienced workforce and potential synergies from the acquisition. The Company allocated the goodwill to its reporting unit. The Company does not expect any portion of this goodwill to be deductible for income tax purposes. Debt As of the Acquisition Date, Corlieve held a loan with outstanding amount equal to EUR 1.0 million ($1.2 million), which loan was repaid in its entirety in September 2021. As of the Acquisition Date, Corlieve also held a loan with outstanding amount equal to EUR 0.4 million ($0.4 million), which was repaid in its entirety in December 2021. Other As of the Acquisition Date, the Company also acquired other assets and assumed other liabilities, which included among others, EUR 2.9 million ($3.4 million) of current assets, which consisted of EUR 2.8 million ($3.3 million) of cash, and EUR 1.1 million ($1.3 million) of current liabilities.

Collaboration arrangements and

Collaboration arrangements and concentration of credit risk	12 Months Ended
Collaboration arrangements and concentration of credit risk	Dec. 31, 2021
Collaboration arrangements and concentration of credit risk
Collaboration arrangements and concentration of credit risk	4. Collaboration arrangements and concentration of credit risk CSL Behring collaboration On the Signing Date, uniQure biopharma B.V., a wholly-owned subsidiary of uniQure N.V., entered into the CSL Behring Agreement with CSL Behring, pursuant to which CSL Behring received exclusive global rights to the Product. On May 6, 2021, a day after the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the CSL Behring Agreement became fully effective (“Closing”). Pursuant to the CSL Behring Agreement, the Company received a $450.0 million upfront cash payment and $12.4 million in other payments related to the Closing and the transfer of the license. The Company is eligible to receive up to $1.6 billion in additional payments based on the achievement of regulatory and commercial milestones. The CSL Behring Agreement also provides that the Company will be eligible to receive tiered double-digit royalties in a range of up to a low-twenties percent of net sales of the Product based on sales thresholds. On the Signing Date, the Company and CSL Behring entered into a development and commercial supply agreement, pursuant to which, among other things, the Company will supply the Product to CSL Behring at an agreed-upon price commensurate with the SSP. The Company will be responsible for supplying development and commercial Product until such time that these capabilities may be transferred to CSL Behring or a designated contract manufacturing organization. The Company will be completing the HOPE-B clinical trial and the validation of the manufacturing process on behalf of CSL Behring, as well as provide further development services if requested by CSL Behring. Activities related to on-demand development services as well as activities related to the completing the HOPE-B clinical trial will be reimbursed by CSL Behring at an agreed full-time-employee rate (“FTE-rate”) and CSL Behring will also reimburse agreed third-party expenses incurred in relation to performing these activities. The validation of the manufacturing process as well as Manufacturing Development will be reimbursed through a future milestone payment. If completed after certain contractually agreed upon dates, the milestone payment will be reduced in accordance with a pre-specified mechanism. The Company concluded that CSL Behring is a customer in accordance with Topic 606. The Company identified two material performance obligations related to the CSL Behring Agreement: (i) License Sale; and (ii) Manufacturing Development. These performance obligations are considered distinct from one another, as CSL Behring can benefit from the identified service either on its own or together with other resources that are readily available to CSL Behring, and as the performance obligations are separately identifiable from other performance obligations in the CSL Behring Agreement. The Company continued to develop the Product between the Signing Date and Closing and performed certain reimbursable activities to fulfill the transfer of the global rights (“Additional Covenants” and together with the License the “License Sale”). The Additional Covenants are not considered distinct from the performance obligation to sell the license to CSL Behring as CSL Behring could not benefit from the Additional Covenants on their own, or have these activities be performed with readily available resources. The Company determined that the fixed upfront payment of $450.0 million and the $12.4 million that the Company received in relation to the Additional Covenants should be allocated to the License Sale. In addition, the Company concluded that variable milestone payments, sales milestone payments and royalties should be allocated to the License Sale performance obligation as well. The Company determined that the License Sale was completed on May 6, 2021, when it transferred the license and CSL Behring assumed full responsibility for the development and commercialization of the Product. At Closing, the Company evaluated the amounts of potential payments and the likelihood that the payments will be received. The Company utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Since the Company cannot control the achievement of regulatory and first commercial sales milestones, the Company concluded that the potential payments are constrained as of Closing. The Company determined that it would recognize revenue related to these payments only to the extent that it becomes probable that no significant reversal of recognized cumulative revenue will occur thereafter. Similarly, the Company will record expenses related to its existing license and other agreements as well as its financial advisor for a high single digit percentage of any such revenue recognized associated to meeting a milestone. The Company will include payments related to sales milestones in the transaction price when their achievement becomes probable, and it will include royalties on the sale of Product once these have been earned. The Company determined that the variable milestone payment related to Manufacturing Development should be allocated to the Manufacturing Development performance obligation. The Company concluded that this milestone payment represents the SSP of the services based on the estimated cost of providing the services including a reasonable margin. The services related to Manufacturing Development will be provided between Closing and the completion of an agreed manufacturing development plan. The variable consideration will be reduced if the Company does not complete the development by pre-agreed dates. The Company utilized the most likely amount method to estimate the variable consideration to be included in the transaction price. Completion of Manufacturing Development is partially dependent on the timing of regulatory submissions by CSL Behring as well as regulatory approvals of the developed manufacturing processes. Since the Company cannot control the timing or outcome of any regulatory decisions, the Company concluded that it would recognize revenue related to this payment when it becomes probable that the milestone has been achieved. The Company has not recognized any revenue related to Manufacturing Development. The Company recognized $2.4 million of collaboration revenue in the year ended December 31, 2021, respectively, compared to nil in the same periods in 2020 and 2019. The Company generates such collaboration revenue from services rendered in relation to completing the HOPE-B clinical trial on behalf of CSL Behring. CSL Behring may request additional development services or request the Company to support the transfer of manufacturing to a party designated by CSL Behring. These collaboration services will be reimbursed at the pre-agreed FTE-rate. The Company incurred $2.1 million of expenses for obligations related to the CSL Behring Agreement that had not been satisfied as of December 31, 2020. The Company capitalized these expenses as contract fulfillment costs (presented within Other current assets). As of December 31, 2020, the Company also recognized a $2.1 million receivable (presented within Accounts receivable) from CSL Behring for expenses for which it has a right of reimbursement as well as a contract liability (presented within Accrued expenses and other current liabilities) for the same amount. In accordance with ASC 606 the Company could not recognize any license revenue related to the CSL Behring Agreement in the period ended December 31, 2020. Following the Closing, the Company collected the $2.1 million of accounts receivable related to reimbursable contract fulfillment costs that was outstanding as of December 31, 2020 . Bristol-Myers Squibb collaboration 2015 Agreement In May 2015, the Company entered into the BMS CLA and various related agreements with BMS, which the Company collectively refers to as the BMS CLA, which provided BMS with exclusive access to the Company’s gene therapy technology platform for the research, development and commercialization of therapeutics aimed at multiple Collaboration Targets. The initial four-year research term under the collaboration terminated on May 21, 2019. During the initial research term of the BMS CLA, the Company supported BMS in discovery, non-clinical, analytical and process development efforts in respect of the Collaboration Targets. For any Collaboration Targets that may be advanced, the Company will be responsible for manufacturing of clinical and commercial supplies. BMS reimbursed the Company for all its research and development costs in support of the collaboration, and will lead development, regulatory and commercial activities for any Collaboration Targets that may be advanced. The BMS CLA initially provided that the Company and BMS could potentially have collaborated on up to ten Collaboration Targets in total. 2020 Amendment On December 1, 2020, the Company and BMS entered into the amended BMS CLA. Under the amended BMS CLA, BMS is limited to four Collaboration Targets. For a period of one-year from the effective date of the amended BMS CLA, BMS was able to replace up to two of the four active Collaboration Targets with two new targets in the field of cardiovascular disease. The Company continues to be eligible to receive research, development, and regulatory milestone payments of up to $217.0 million for each Collaboration Target, if defined milestones are achieved. Since the December 2020 amendment, BMS is no longer entitled to designate the fifth to tenth Collaboration Targets and as such the Company’s remaining obligations under the amended BMS CLA are substantially reduced. The Company is also no longer entitled to receive up to an aggregate $16.5 million in target designation payments for the research, development and regulatory milestone payments associated with the fifth to tenth Collaboration Targets. For as long as any of the four Collaboration Targets are being advanced, BMS may place a purchase order to be supplied with research, clinical and commercial supplies. Subject to the terms of the amended BMS CLA, BMS has the right to terminate the research, clinical and commercial supply relationships, and has certain remedies for failures of supply, up to and including technology transfer for any such failure that otherwise cannot be reasonably resolved. Both BMS and the Company may agree to a technology transfer of manufacturing capabilities pursuant to the terms of the amended BMS CLA. The amended BMS CLA does not extend the initial four-year research term that expired in May 2019. BMS may place purchase orders to provide limited services primarily related to analytical and development efforts in respect of the four Collaboration Targets. BMS may request such services for a period not to exceed the earlier of (i) the completion of all activities under a Research Plan and (ii) November 30, 2023, if no replacement targets are designated. BMS continues to reimburse the Company for these services. During the year ended December 31, 2020, the Company evaluated the impact of the amendment of the BMS CLA had in relation to its performance obligation related to License Revenue. The Company did not identify any new distinct performance obligations and determined the amended BMS CLA did not represent a separate contract in accordance with ASC 606. The Company evaluated the effect the modification had on its measure of progress towards the completion of its performance obligation related to License Revenue and determined that its remaining performance obligation under the amended BMS CLA was immaterial and recognized the remaining balance of unrecognized License Revenue as of November 30, 2020. Services to BMS are rendered by the Dutch operating entity. Total collaboration and license revenue generated with BMS are as follows (presented as revenue from a related party up until the effective date of the amended BMS CLA and presented as revenue after the effective date): Years ended December 31, 2021 2020 2019 (in thousands) Bristol Myers Squibb $ 4,176 $ 37,514 $ 7,281 $ 4,176 $ 37,514 $ 7,281 Amounts owed by BMS in relation to the Collaboration and License Revenue are as follows (presented as “Accounts receivables” as of December 31, 2021 and 2020: December 31, December 31, 2021 2020 (in thousands) Bristol Myers Squibb $ 914 $ 4,536 Total $ 914 $ 4,536 Collaboration Revenue The Company recognizes collaboration revenues associated with Collaboration Target-specific pre-clinical analytical development and process development activities that are reimbursable by BMS under the BMS CLA and the amended BMS CLA as well as other related agreements. Collaboration Revenue related to these contracted services is recognized when performance obligations are satisfied. The Company generated $4.2 million collaboration revenue for the year ended December 31, 2021 (December 31, 2020: $0.2 million; December 31, 2019: $2.3 million). License Revenue The Company recognized no License Revenue for the year ended December 31, 2021 (December 31, 2020: $33.0 million, December 31, 2019: $5.0 million). On May 21, 2015, the Company recorded a $60.1 million upfront payment and in August 2015 it recorded a $15.0 million payment it received from BMS in relation to the designation of the second, third and fourth Collaboration Targets. The Company recognized License Revenue over the expected performance period based on its measure of progress towards the completion of certain activities related to its services. The Company determined such progress by comparing activities performed at the end of each reporting period with total activities expected to be performed. The Company estimated total expected activities using several unobservable inputs, such as the probability of BMS designating additional targets, the probability of successfully completing each phase and estimated time required to provide services during the various development stages. The estimation of total services at the end of each reporting period involves considerable judgment. The amount of services the Company expects to provide is significantly impacted by the number of Collaboration Targets that it estimates BMS would pursue. As a result of the December 1, 2020 amendment of the BMS CLA the Company no longer is required to potentially provide any services in relation to six additional targets that BMS might have designated. The Company determined its remaining performance obligation is immaterial. The Company adjusted its measure of progress towards the completion of its activities related to its services as of the December 1, 2020 modification date accordingly. The Company recognized the remaining balance of unrecognized License Revenue as of November 30, 2020 of $27.8 million in profit and loss during the year ended December 31, 2020 as License Revenue from a related party. The Company includes variable consideration related to any research, development, and regulatory milestone payments, in the transaction price once it is considered probable that including these payments in the transaction price would not result in the reversal of cumulative revenue recognized. Due to the significant uncertainty surrounding the development of gene-therapy product candidates and the dependence on BMS’s performance and decisions, the Company does not currently consider this probable. However, there was a milestone that was recorded as license revenue in the year ended December 31, 2020 (see below). On December 17, 2020 BMS designated one of the four Collaboration Targets as a candidate to advance into Investigational New Drug-enabling studies (“IND-enabling studies”) entitling the Company to receive a $4.4 million research milestone payment. The Company recorded the $4.4 million as License Revenue in the year ended December 31, 2020. The Company recognizes License Revenue related to product sales by BMS from any of the Collaboration Targets when the sales occur. The Company is eligible to receive net sales-based milestone payments and tiered mid-single to low double-digit royalties on product sales. The royalty term is determined on a licensed-product-by-licensed-product and country-by-country basis and begins on the first commercial sale of a licensed product in a country and ends on the expiration of the last to expire of specified patents or regulatory exclusivity covering such licensed product in such country or, with a customary royalty reduction, ten years after the first commercial sale if there is no such exclusivity.

Fair value measurement and Othe

Fair value measurement and Other non-operating (losses) gains	12 Months Ended
	Dec. 31, 2021
Fair value measurement and Other non-operating (losses) / gains
Fair value measurement and Other non-operating (losses) / gains	5. Fair value measurement and Other non-operating (losses) / gains The Company measures certain financial assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. The carrying amount of cash and cash equivalents, accounts receivable from collaborators, prepaid expenses, other assets, accounts payable, accrued expenses and other current liabilities reflected in the consolidated balance sheets approximate their fair values due to their short-term maturities. The Company’s only material financial assets measured at fair value using Level 1 inputs is cash and cash equivalents and restricted cash. Restricted cash is included within “Other non-current assets” within the consolidated balance sheets. The following table sets forth the balances and changes in fair values of liabilities that are measured at fair value using Level 3 inputs: Derivative Contingent financial consideration instruments Total (in thousands) Balance at December 31, 2018 $ — $ 1,375 $ 1,375 Net losses recognized in profit or loss — 2,530 2,530 Exercise of Hercules warrants — (770) (770) Currency translation effects — (60) (60) Balance at December 31, 2019 $ — $ 3,075 $ 3,075 Net gains recognized in profit or loss — (2,300) (2,300) Derecognition of BMS warrants — (796) (796) Recognition of derivative financial liability of CoC-payment — 2,613 2,613 Currency translation effects — 53 53 Balance at December 31, 2020 $ — $ 2,645 $ 2,645 Amount recorded for contingent consideration on Acquisition Date of Corlieve 23,950 — 23,950 Net losses recognized in profit or loss 6,683 160 6,843 Currency translation effects (1,091) — (1,091) Balance at December 31, 2021 $ 29,542 $ 2,805 $ 32,347 Derivative financial instruments The Company issued derivative financial instruments related to its collaboration with BMS and in relation to the issuance of the Hercules loan facility. The Company recorded the following results in other non-operating (losses) / gains related to the changes in the fair value of derivative financial instruments. Years ended December 31, 2021 2020 2019 (in thousands) Other non-operating gains: Derivative gains $ — $ 483 $ — Total other non-operating gains: — 483 — Other non-operating losses: Derivative losses (160) — (2,530) Total other non-operating losses: (160) — (2,530) Other non-operating (losses) / gains, net $ (160) $ 483 $ (2,530) Derivative financial instruments BMS Pursuant to the BMS CLA, the Company in 2015 granted BMS two warrants that were subsequently terminated in connection with the amendment to the BMS CLA on December 1, 2020. The Company granted to BMS: ● A warrant that allowed BMS to purchase a specific number of the Company’s ordinary shares such that its ownership would have equaled 14.9% immediately after such purchase (“1 st warrant”). The 1 st warrant could have been exercised on the later of (i) the date on which the Company received from BMS the Target Designation Fees (as defined in the BMS CLA) associated with the first six new targets (a total of seven Collaboration Targets); and (ii) the date on which BMS designated the sixth new target (the seventh Collaboration Target); and ● A warrant that allowed BMS to purchase a specific number of the Company’s ordinary shares such that its ownership would have equaled 19.9% immediately after such purchase (“2 nd warrant” and together with 1 st warrant, the “warrants”). The warrant could have been exercised on the later of (i) the date on which the Company received from BMS the Target Designation Fees associated with the first nine new targets (a total of ten Collaboration Targets); and (ii) the date on which BMS designated the ninth new target (the tenth Collaboration Target). On December 1, 2020, the Company derecognized the warrants when these were terminated in accordance with the amended BMS CLA. Pursuant to the terms of the BMS CLA the exercise price in respect of each warrant was equal to the greater of (i) the product of (A) $33.84 , multiplied by (B) a compounded annual growth rate of 10% (or approximately $57.32 as of November 30, 2020) and (ii) the product of (A) 1.10 multiplied by (B) the weighted average volume price (“VWAP”) for the 20 trading days ending on the date that is five trading days prior to the date of a notice of exercise delivered by BMS. The fair value of the warrants as of December 31, 2019 was $3.1 million. During the year ended December 31, 2020, the Company recognized a $3.1 million gain in non-operating (losses) / gains (December 31, 2019: $2.3 million loss) related to fair value changes of the BMS warrants. The gain recognized in the year ended December 31, 2020 includes $0.8 million from the derecognition of the BMS warrants on December 1, 2020. The Company used Monte-Carlo simulations to determine the fair market value of the BMS warrants. The valuation model incorporated several inputs, the risk-free rate adjusted for the period affected, an expected volatility based on historical Company volatility, the expected yield on any dividends and management’s expectations on the timelines of reaching certain defined trigger events for the exercising of the warrants, as well as management’s expectations regarding the number of ordinary shares that would be issued upon exercise of the warrants. All of these represent Level 3 inputs. Additionally, the model assumed BMS would exercise the warrants only if it was financially rational to do so. The warrants could only have been exercised following the occurrence of events contractually defined in the warrant agreements. The probability of the occurrence of these events represented another significant unobservable input used in the calculation of the fair value of the warrants. On December 1, 2020, the Company and BMS agreed that upon the consummation of a change of control transaction of uniQure that occurs prior to December 1, 2026 or BMS’ delivery of a target cessation notice for all four Collaboration Targets, the Company (or its third party acquirer) shall pay to BMS a one-time, non-refundable, non-creditable cash payment of $70.0 million, provided that (x) if $70.0 million is greater than five percent (5.0%) of the net proceeds (as contractually defined) from such change of control transaction, the payment shall be an amount equal to five percent of such net proceeds, and (y) if $70.0 million is less than one percent of such net proceeds, the change of control payment shall be an amount equal to one percent of such net proceeds (“CoC-payment”). The Company has not consummated any change of control transaction as of December 31, 2021 that would obligate it to make a CoC-payment. The Company determined that the CoC-payment should be recorded as a derivative financial liability as of December 1, 2020 and that subsequent changes in the fair market value of this derivative financial liability should be recorded in profit and loss. The fair market value of the derivative financial liability is materially impacted by probability that market participants assign to the likelihood of the occurrence of a change of control transaction that would give rise to a CoC-payment. This probability represents an unobservable input. The Company determined the fair market value of the derivative financial liability by using a present value model based on expected cash flow. The expected cash flows are materially impacted by the probability that market participants assign to the likelihood of the occurrence of a change of control transaction within the biotechnology industry. The Company estimated this unobservable input using the best information available as of December 1, 2020, and December 31, 2020 and 2021, respectively. The Company obtained reasonably available market information that it believed market participants would use in determining the likelihood of the occurrence of a change-of control transaction within the biotechnology industry. Selecting and evaluating market information involves considerable judgment and uncertainty. Based on all such information and its judgment, the Company estimated that the fair market value of the derivative financial liability (presented within “Other non-current liabilities”) as of December 31, 2021 was $2.8 million (December 1, 2020 and December 31, 2020: $2.6 million). The Company recorded a $2.6 million loss within “Other non-operating (losses) / gains” in the year ended December 31, 2020 related to the initial recognition of this derivative financial liability. The increase of the fair market value of the derivative financial liability of $0.2 million in the year ended December 31, 2021 was recorded in Other non-operating (losses) / gains. Hercules loan facility In 2013 the Company entered into a venture debt loan facility with Hercules (see Note 10, “ Long-term debt Contingent consideration Corlieve transaction The Company is required to pay up to EUR 178.8 million ($202.8 million at the December 31, 2021 foreign exchange rate) to the former shareholders of Corlieve upon the achievement of contractually defined milestones in connection with the Company’s acquisition of Corlieve (refer to Note 3 “Corlieve transaction” The fair value of the contingent consideration as of December 31, 2021 was $29.5 million using discount rates ranging from 10.9% to 11.9% as well as a 55% likelihood of AMT-260 advancing into clinical development by no later than early 2024. The Company increased the likelihood of advancing into clinical development from 40% to 55% following the designation of a lead candidate in late October 2021, which resulted in EUR 5.0 million ($5.8 million) increase of the contingent liability. If as of December 31, 2021 the Company had assumed a 100% likelihood of AMT-260 advancing into clinical development, then the fair value of the contingent consideration would have increased to $47.0 million. If as of December 31, 2021 the Company assumed that it would discontinue development of the AMT-260 program, then the contingent consideration would be released to income. Changes in fair value of the contingent liability are recognized within research and development expenses in the consolidated statements of operations. Other As of December 31, 2021, the Company recorded $0.8 million related to consideration for post-acquisition services, presented within Other non-current liabilities in connection with the Company’s acquisition of Corlieve. Other

Property, plant and equipment,

Property, plant and equipment, net	12 Months Ended
Property, plant and equipment, net	Dec. 31, 2021
Property, plant and equipment, net
Property, plant and equipment, net	6. Property, plant, and equipment, net The following table presents the Company’s property, plant, and equipment as of December 31: December 31, December 31, 2021 2020 (in thousands) Leasehold improvements $ 45,372 $ 37,849 Laboratory equipment 25,499 22,106 Office equipment 4,465 5,025 Construction-in-progress 5,069 2,574 Total property, plant, and equipment 80,405 67,554 Less accumulated depreciation (36,900) (35,226) Property, plant and equipment, net $ 43,505 $ 32,328 Total depreciation expense was $6.1 million for the year ended December 31, 2021 (December 31, 2020: $5.7 million, December 31, 2019: $6.0 million). Depreciation expense is allocated to research and development expenses to the extent it relates to the Company’s manufacturing facility and equipment and laboratory equipment. All other depreciation expenses are allocated to selling, general and administrative expense. The following table summarizes property, plant, and equipment by geographic region. December 31, December 31, 2021 2020 (in thousands) Lexington, Massachusetts (United States of America) $ 17,311 $ 15,949 Amsterdam (the Netherlands) 26,160 16,379 Other 34 - Total $ 43,505 $ 32,328

Right-of-use asset and lease li

Right-of-use asset and lease liabilities	12 Months Ended
Right-of-use asset and lease liabilities	Dec. 31, 2021
Right-of-use asset and lease liabilities
Right-of-use asset and lease liabilities	7. Right-of-use asset and lease liabilities The Company’s most significant leases relate to office and laboratory space under the following operating lease agreements: Lexington, Massachusetts / United States In July 2013, the Company entered into a lease for a facility in Lexington, Massachusetts, United States. The term of the lease commenced in November 2013, was set for 10 years starting from the 2014 rent commencement date and is non-cancellable. Originally, the lease for this facility had a termination date of 2024. In November 2018, the term was expanded by five years to June 2029. The lease continues to be renewable for two subsequent five-year terms. Additionally, the lease was expanded to include an additional 30,655 square feet within the same facility and for the same term. The lease of the expansion space commenced on June 1, 2019. The contractually fixed annual increase of lease payments through 2029 for both the extension and expansion lease have been included in the lease payments. In December 2021, the Company entered into a new lease for an additional facility in Lexington, Massachusetts, United States of approximately 13,501 square feet of space. The lease is expected to commence in the second half of 2022, is set for seven years starting from the rent commencement date and is non-cancellable. The lease is renewable for one five-year term. Amsterdam / The Netherlands In March 2016, the Company entered into a 16-year lease for a facility in Amsterdam, the Netherlands and amended this agreement in June 2016. The lease for the facility terminates in 2032, with an option to extend in increments of five-year periods. The lease contract includes variable lease payments related to annual increases in payments based on a consumer price index. On December 1, 2017, the Company entered into an agreement to sub-lease three of the seven floors of its Amsterdam facility for a ten-year term ending on December 31, 2027, with an option for the sub-lessee to extend until December 31, 2031. In February 2020, the Company amended the agreement to sub-lease to take back one of the three floors effective March 1, 2020. The fixed lease payments to be received during the remaining term under the agreement to sub-lease amount to $5.4 million (EUR 4.7 million) as of December 31, 2021. In May 2021, the Company entered into a sublease agreement to let an additional approximately 1,080 square meters of office space to accommodate the hiring of additional full-time employees. The lease expires in October 2028 and includes an option to break the lease on October 31, 2023. Operating lease liabilities Year ended December 31, 2021 2020 2019 (in thousands) Operating lease cost $ 5,306 $ 5,052 $ 4,474 Variable lease cost 698 607 507 Sublease income (907) (904) (1,053) Total lease cost $ 5,097 $ 4,755 $ 3,928 The table below presents the lease-related assets and liabilities recorded on the Consolidated balance sheets in accordance with the new lease accounting standard. December 31, December 31, 2021 2020 (in thousands) Assets Operating lease right-of-use assets $ 25,573 26,086 Liabilities Current Current operating lease liabilities 5,774 5,524 Non-current Non-current operating lease liabilities 28,987 30,403 Total lease liabilities $ 34,761 35,927 Other information The weighted-average remaining lease term as of December 31, 2021, is 8.3 years, compared to 9.4 years as of December 31, 2020, and the weighted-average discount rate as of December 31, 2021 is 11.34% , compared to 11.37% as of December 31, 2020. The Company uses an incremental borrowing rate applicable to the lease asset. The table below presents supplemental cash flow and non-cash information related to leases. Year ended December 31, 2021 2020 2019 (in thousands) Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases 1) $ 5,738 $ 5,769 $ 4,717 Right-of-use asset obtained in exchange for lease obligation Operating lease 2) $ 1,699 $ — $ 9,002 1) 2) Undiscounted cash flows The table below reconciles the undiscounted cash flows as of December 31, 2021, for each of the first five years and the total of the remaining years to the operating lease liabilities recorded on the Consolidated balance sheet as of December 31, 2021. Lexington Amsterdam (1) Total (in thousands) 2022 $ 3,552 $ 2,222 $ 5,774 2023 3,650 2,668 6,318 2024 4,146 2,112 6,258 2025 4,465 2,112 6,577 2026 4,600 2,112 6,712 Thereafter 11,680 9,736 21,416 Total lease payments $ 32,093 $ 20,962 $ 53,055 Less: amount of lease payments representing interest payments (10,251) (8,043) (18,294) Present value of lease payments 21,842 12,919 34,761 Less: current operating lease liabilities (3,552) (2,222) (5,774) Non-current operating lease liabilities $ 18,290 $ 10,697 $ 28,987 (1) Payments are due in EUR and have been translated at the foreign exchange rate as of December 31, 2021, of $1.13 / €1.00)

Intangible assets, net and Good

Intangible assets, net and Goodwill	12 Months Ended
Intangible assets, net and Goodwill	Dec. 31, 2021
Intangible assets, net and Goodwill
Intangible assets, net and Goodwill	8. Intangible assets, net and Goodwill The following table presents the Company’s acquired licenses and acquired IPR&D as of December 31: December 31, December 31, 2021 2020 (in thousands) Acquired licenses $ 4,755 $ 5,660 Less accumulated amortization (2,827) (2,299) Acquired licenses, net $ 1,928 $ 3,361 Acquired IPR&D Intangible Asset 60,758 — Intangibles, net $ 62,686 $ 3,361 a. Acquired licenses All acquired licenses are owned by uniQure biopharma B.V, a subsidiary of the Company. The acquired licenses have a weighted average remaining life of 10.8 years as of December 31, 2021. During the year ended December 31, 2020, the Company capitalized $2.2 million of expenditures related to costs incurred in relation to rights to exclusively evaluate certain technologies during a two-year period that commenced on February 1, 2020. During the same period, the Company disposed of a number of licenses determined to have no alternative future use. As of December 31, 2021, the estimated future amortization expense for each of the five succeeding years and the period thereafter is as follows: Years Amount (in thousands) 2022 $ 395 2023 133 2024 133 2025 133 2026 133 Thereafter 1,001 Total $ 1,928 The amortization expense related to licenses for the year ended December 31, 2021 was $1.2 million (December 31, 2020: $4.6 million; December 31, 2019: $0.6 million). The impairment expense related to licenses for the year ended December 31, 2021 was $0.0 million (December 31, 2020: $0.3 million; December 31, 2019 $0.0 million). b. Acquired in-process research and development As part of its acquisition of Corlieve as of July 30, 2021, the Company identified certain intangible assets related to an IPR&D Intangible Asset. Refer to Note 3 “Corlieve transaction” c. Goodwill As part of its acquisition of Corlieve as of July 30, 2021, the Company recorded goodwill. Refer to Note 3 “Corlieve transaction”

Accrued expenses and other curr

Accrued expenses and other current liabilities	12 Months Ended
Accrued expenses and other current liabilities	Dec. 31, 2021
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities	9. Accrued expenses and other current liabilities Accrued expenses and other current liabilities include the following items: December 31, December 31, 2021 2020 (in thousands) Accruals for goods received from and services provided by vendors-not yet billed $ 13,012 $ 8,269 Personnel related accruals and liabilities 12,603 7,687 Accrued contract fulfillment costs and costs to obtain a contract 2,872 — Contract liability (see Note 4. "Collaboration arrangements and concentration of credit risk") — 2,082 Total $ 28,487 $ 18,038

Long-term debt

Long-term debt	12 Months Ended
Long-term debt	Dec. 31, 2021
Long-term debt
Long-term debt	10. Long-term debt On June 14, 2013, the Company entered into a venture debt loan facility with Hercules Capital, Inc. (formerly known as Hercules Technology Growth Capital, Inc.) (“Hercules”), which was amended and restated on June 26, 2014, and again on May 6, 2016 (“2016 Amended Facility”). On December 6, 2018, the Company signed an amendment that both refinanced the then-existing $20.0 million 2016 Amended Facility and allowed the Company to draw down an additional $15.0 million (“2018 Amended Facility”). The 2018 Amended Facility extended the loan’s maturity date from May 1, 2020 until June 1, 2023. The interest rate is adjustable and is the greater of (i) 8.85% and (ii) 8.85% plus the prime rate less 5.50% per annum. Under the 2018 Amended Facility, the Company owes a back-end fee of 4.95% of the outstanding debt. In addition, in May 2020 the Company paid a back-end fee of $1.0 million in relation to the 2016 Amended Facility. On January 29, 2021, the Company and Hercules amended the 2018 Amended Facility (“2021 Amended Facility”). Pursuant to the 2021 Amended Facility, Hercules agreed to an additional Facility of $100.0 million (“Tranche B”) increasing the aggregate principal amount of the term loan facilities from $35.0 million to up to $135.0 million. On January 29, 2021, the Company drew down $35.0 million of the Tranche B. Advances under Tranche B bore interest at a rate equal to the greater of (i) 8.25% or (ii) 8.25% plus the prime rate, less 3.25% per annum. The principal balance of $70.0 million and all accrued but unpaid interest on advances under Tranche B was due on June 1, 2023, which date could had been extended by the Company by up to two twelve-month periods. Advances under the 2021 Amended Facility could have been prepaid without charge after July 29, 2021. The back-end fee in respect of advances under the 2021 Amended Facility ranged from 1.65% to 6.85%, depending on the repayment date. In addition to Tranche B, the 2021 Amended Facility had also extended the interest only payment period of the previously funded $35.0 million term loan (“Tranche A”) from January 1, 2022 to June l, 2023. On December 15, 2021, the Company and Hercules amended and restated the 2021 Amended Facility (“2021 Restated Facility”). Pursuant to the 2021 Restated Facility, Tranche A and Tranche B of the 2021 Amended Facility with a total outstanding balance of $70.0 million were consolidated into one tranche with a total commitment of $100.0 million. The Company drew down an additional $30.0 million, resulting in total principal outstanding as of December 31, 2021 of $100.0 million. The 2021 Restated Facility extended the loan’s maturity date from June 1, 2023 until December 1, 2025. The interest-only period is extended from January 1, 2023 to December 1, 2024, or December 1, 2025 if, prior to June 30, 2024, either (a) the BLA for AMT-061 is approved by the FDA or (b) AMT-130 is advanced into a pivotal trial. The interest rate is adjustable and is the greater of (i) 7.95% and (ii) 7.95% plus the prime rate less 3.25% per annum. Under the 2021 Restated Facility, the Company owes a back-end fee of 4.85% of the outstanding debt. The Company is required to repay the facility in equal monthly installments of principal and interest between the end of the interest-only period and the maturity date. The Company continues to owe a $2.5 million back-end fee related to the 2021 Amended Facility which is due on June 1, 2023. The amortized cost (including interest due presented as part of accrued expenses and other current liabilities) of the 2021 Amended Facility was $101.6 million as of December 31, 2021, compared to an amortized cost of $35.9 million for the 2018 Amended Facility as of December 31, 2020, and is recorded net of discount and debt issuance costs. The foreign currency loss on the loan was $5.3 million in 2021 (2020: gain of $3.1 million; 2019: loss of $0.7 million). The fair value of the loan approximates its carrying amount. Inputs to the fair value of the loan are considered Level 3 inputs. Interest expense recorded during the years ended December 31 was as follows: Years Amount (in millions) 2021 $ 7.2 2020 3.7 2019 3.7 As a covenant in the 2021 Restated Facility the Company has periodic reporting requirements and is required to keep a minimum cash balance deposited in bank accounts in the United States, equivalent to the lesser of (i) 65% of the outstanding balance of principal due or (ii) 100% of worldwide cash and cash equivalents. This restriction on cash and cash equivalents only relates to the location of the cash and cash equivalents, and such cash and cash equivalents can be used at the discretion of the Company. The Company, beginning on April 1, 2023, is also required to keep a minimum of unrestricted cash of at least 50% of the loan amount outstanding. If, prior to June 30, 2024, either (a) the BLA for AMT-061 is approved by the FDA or (b) AMT-130 is advanced into a pivotal trial, the minimum cash covenant will be lowered to at least 30% of the loan amount outstanding and its effectiveness will be deferred to April 1, 2024. In combination with other covenants, the 2021 Restated Facility restricts the Company’s ability to, among other things, incur future indebtedness and obtain additional debt financing, to make investments in securities or in other companies, to transfer assets, to perform certain corporate changes, to make loans to employees, officers, and directors, and to make dividend payments and other distributions to its shareholders. The Company secured the facilities by directly or indirectly pledging its total assets of $809.2 million with the exception of $103.2 million of cash and cash equivalents and other current assets held by uniQure N.V. The 2021 Restated Facility contain provisions that include the occurrence of a material adverse effect, as defined therein, which would entitle Hercules to declare all principal, interest and other amounts owed by the Company immediately due and payable. As of December 31, 2021, the Company was in material compliance with all covenants and provisions. The aggregate maturities of the loans, including $35.6 million of coupon interest payments and financing fees, for each of the 47 months after December 31, 2021, are as follows: Years Amount (in thousands) 2022 $ 7,984 2023 10,580 2024 15,474 2025 101,549 Total $ 135,587

Shareholders' equity

Shareholders' equity	12 Months Ended
Shareholders' equity	Dec. 31, 2021
Shareholders' equity
Shareholders' equity	11. Shareholders’ equity As of December 31, 2021, the Company’s authorized share capital is €4.0 million (or $4.5 million when translated at an exchange rate as of December 31, 2021, of $1.13 / €1.00), divided into 80,000,000 ordinary shares, each with a nominal value of €0.05. The Company’s shareholders, at the 2021 Annual General Meeting of Stockholders held on June 16, 2021, approved an increase in the number of authorized ordinary shares by 20,000,000 to 80,000,000 million. All ordinary shares issued by the Company were fully paid. Besides the minimum amount of share capital to be held under Dutch law, there are no distribution restrictions applicable to the equity of the Company. As of December 31, 2021, and 2020 and 2019 the Company’s other comprehensive result was restricted for payment of dividends for an accumulated other comprehensive loss of $28.9 million in 2021, an accumulated other comprehensive gain of $9.9 million in 2020, and an accumulated other comprehensive loss of $6.7 million in 2019. On March 1, 2021, the Company entered into a Sales Agreement with SVB Leerink LLC (“SVB Leerink”) with respect to an at-the-market (“ATM”) offering program, under which the Company may, from time to time in its sole discretion, offer and sell through SVB Leerink, acting as agent, its ordinary shares, up to an aggregate offering price of $200.0 million. The Company will pay SVB Leerink a commission equal to 3% of the gross proceeds of the sales price of all ordinary shares sold through it as sales agent under the Sales Agreement. In March and April 2021, the Company issued an aggregate of 921,730 ordinary shares at a weighted average price of $33.52 per ordinary share, with net proceeds of $29.6 million, after deducting underwriting discounts and net of offering expenses. The Company defers direct, incremental costs associated to this offering, except for the commission costs to SVB Leerink, which are a reduction to additional paid-in capital, and will deduct these costs from additional paid-in capital in the consolidated balance sheets proportionately to the amount of proceeds raised. During the year ended December 31, 2021, $1.3 million of direct, incremental costs were deducted from additional paid-in capital. Following the Closing of the CSL Behring transaction, the Company consumed its tax net operating loss carryforwards from the years 2011 to 2018. The Company allocated the tax benefit from the release of the valuation allowance related to net operating loss carryforwards generated by share issuance costs incurred in 2014, 2015, 2017 and 2018 to additional paid-in capital. This resulted in an increase of additional paid-in capital of $3.0 million in the year ended December 31, 2021. In February 2019, the Company issued 37,175 ordinary shares to Hercules pursuant to exercised warrants for $0.5 million in aggregate cash consideration. The Company deemed the sale and issuance of these shares to be exempt from registration under the Securities Act in reliance on Regulation S of the Securities Act, as an offshore offering of securities and such shares were issued as restricted shares. Hercules represented to us that they were in compliance with the requirements of Regulation S.

Share-based compensation

Share-based compensation	12 Months Ended
Share-based compensation	Dec. 31, 2021
Share-based compensation
Share-based compensation	12. Share-based compensation Share-based compensation expense recognized by classification included in the consolidated statements of operations and comprehensive loss was as follows: Year ended December 31, 2021 2020 2019 (in thousands) Research and development $ 12,813 $ 11,965 $ 8,029 Selling, general and administrative 12,794 9,823 9,439 Total $ 25,607 $ 21,788 $ 17,468 Share-based compensation expense recognized by award type was as follows: Year ended December 31, 2021 2020 2019 (in thousands) Award type Share options $ 12,477 $ 11,434 $ 7,896 Restricted share units 11,347 7,364 4,117 Performance share units 1,783 2,990 5,455 Total $ 25,607 $ 21,788 $ 17,468 As of December 31, 2021, the unrecognized compensation cost related to unvested awards under the various share-based compensation plans were: Unrecognized Weighted average share-based remaining compensation period for expense recognition (in thousands) (in years) Award type Share options $ 29,513 2.79 Restricted share units 19,348 2.00 Performance share units 781 0.63 Total $ 49,642 2.45 The Company satisfies the exercise of share options and vesting of Restricted Share Units (“RSUs”) and Performance Share Units (“PSUs”) through newly issued shares. The Company’s share-based compensation plans include the 2014 Amended and Restated Share Option Plan (the “2014 Plan”) and inducement grants under Rule 5653(c)(4) of The Nasdaq Global Select Market with terms similar to the 2014 Plan (together the “2014 Plans”). The Company previously had a 2012 Equity Incentive Plan (the “2012 Plan”). As of December 31, 2021, 14,000 fully vested share options are outstanding (December 31, 2020: 14,000) under the 2012 Plan. At the general meeting of shareholders on January 9, 2014, the Company’s shareholders approved the adoption of the 2014 Plan. At the annual general meetings of shareholders in June 2015, 2016, 2018 and 2021, uniQure shareholders approved amendments of the 2014 Plan, increasing the shares authorized for issuance by 1,070,000 shares in 2015, 3,000,000 in 2016, 3,000,000 shares in 2018 and 4,000,000 shares in 2021 for a total of 12,601,471 shares. Share options Share options are priced on the date of grant and, except for certain grants made to non-executive directors, vest over a period of four years . The first 25% vests after one year from the initial grant date and the remainder vests in equal quarterly installments over years two, three and four. Certain grants to non-executive directors vest in full after one year . Any options that vest must be exercised by the tenth anniversary of the initial grant date. 2014 Plan The following tables summarize option activity under the Company’s 2014 Plans for the year ended December 31, 2021: Options Number of Weighted average Weighted average Aggregate intrinsic ordinary shares exercise price remaining contractual life value in years (in thousands) Outstanding at December 31, 2020 2,659,279 $ 28.13 7.18 $ 32,729 Granted 1,174,893 $ 35.85 Forfeited (258,718) $ 40.78 Expired (25,633) $ 42.81 Exercised (241,496) $ 10.98 Outstanding at December 31, 2021 3,308,325 $ 31.02 7.05 8,660 Thereof, fully vested and exercisable at December 31, 2021 1,786,825 $ 24.47 5.49 8,640 Thereof, outstanding and expected to vest after December 31, 2021 1,521,500 $ 38.71 8.88 20 Outstanding and expected to vest at December 31, 2020 1,116,874 $ 42.06 Total weighted average grant date fair value of options issued during the period (in $ millions) $ 24.6 Granted to directors and officers during the period (options, grant date fair value $ in millions) 312,704 $ 6.5 Proceeds from option sales during the period (in $ millions) $ 2.7 The following table summarizes information about the weighted average grant-date fair value of options during the years ended December 31: Weighted average Options grant ‑ date fair value Granted, 2021 1,174,893 $ 20.95 Granted, 2020 653,852 28.08 Granted, 2019 647,526 23.57 Vested, 2021 507,503 22.17 Forfeited, 2021 (258,718) 23.60 The following table summarizes information about the weighted average grant-date fair value of options at December 31: Weighted average Options grant ‑ date fair value Outstanding and expected to vest, 2021 1,521,500 $ 22.52 Outstanding and expected to vest, 2020 1,116,874 24.25 The fair value of each option issued is estimated at the respective grant date using the Hull & White option pricing model with the following weighted-average assumptions: Year ended December 31, Assumptions 2021 2020 2019 Expected volatility 75% 70% 70% - 75% Expected terms 10 years 10 years 10 years Risk free interest rate 1.21 - 1.86% 0.76% - 1.44% 1.92% - 2.87% Expected dividend yield 0% 0% 0% The Hull & White option model captures early exercises by assuming that the likelihood of exercises will increase when the share price reaches defined multiples of the strike price. This analysis is performed over the full contractual term. The following table summarizes information about options exercised during the years ended December 31: Exercised during the year Intrinsic value (in thousands) 2021 241,496 $ 5,046 2020 498,678 11,927 2019 434,665 17,700 Restricted Share Units The following table summarizes the RSU activity for the year ended December 31, 2021: RSU Weighted average Number of grant-date fair ordinary shares value Non-vested at December 31, 2020 467,344 $ 43.56 Granted 574,921 $ 36.14 Vested (220,518) $ 40.56 Forfeited (111,130) $ 40.98 Non-vested at December 31, 2021 710,617 $ 38.89 Total weighted average grant date fair value of RSUs granted during the period (in $ millions) $ 20.8 Granted to directors and officers during the period (shares, $ in millions) 167,230 $ 6.1 The following table summarizes information about the weighted average grant-date fair value of RSUs granted during the years ended December 31: Granted Weighted average during the year grant ‑ date fair value 2021 574,921 $ 36.14 2020 376,799 48.18 2019 198,504 38.63 The following table summarizes information about the total fair value of RSUs that vested during the years ended December 31: Total fair value (in thousands) 2021 $ 8,063 2020 12,156 2019 10,152 RSUs generally vest over one to three years . RSUs granted to non-executive directors will vest one year from the date of grant. Performance Share Units The following table summarizes the PSU activity for the year ended December 31, 2021: PSU Weighted average Number of grant-date fair ordinary shares value Non-vested at December 31, 2020 212,614 $ 42.32 Granted 555,600 30.19 Vested (132,368) $ 33.09 Forfeited (2,916) $ 57.56 Non-vested at December 31, 2021 632,930 $ 33.54 Total weighted average grant date fair value of PSUs granted during the period (in $ millions) $ 16.8 The Company granted shares to certain employees in September and December 2021 that will be earned upon achievement of defined milestones. Earned shares will vest upon the later of a minimum service period of one year or three years , or the achievement of defined milestones, subject to the grantee’s continued employment. In addition, portions of the December 2021 granted to executives and other members of senior management are subject to achieving a minimum total shareholder return relative to the Nasdaq biotechnology index. The Company recognizes the compensation cost related to these grants to the extent it considers achievement of the milestones to be probable. In January 2018 and January and February 2019, the Company awarded PSUs to its executives and other members of senior management. These PSUs were earned in January 2019 and January 2020, based on the Board’s assessment of the level of achievement of agreed upon performance targets through December 31, 2018, and December 31, 2019, respectively. The PSUs awarded for the year ended December 31, 2018 vested in February 2021 and the PSUs awarded for the year ended December 31, 2019 vested in January 2022. The following table summarizes information about the weighted average grant-date fair value of the PSUs determined as of the date these were earned for the 2018 and 2019 PSUs, and the date of the grant for the 2021 PSUs: Granted Weighted average during the year grant ‑ date fair value 2021 555,600 $ 30.19 2020 91,003 $ 57.56 2019 132,362 $ 31.71 The following table summarizes information about the total fair value of PSUs that vested during the years ended December 31: Total fair value (in thousands) 2021 $ 5,074 2020 21,852 2019 1,056 Employee Share Purchase Plan (“ESPP”) In June 2018, the Company’s shareholders adopted and approved an ESPP allowing the Company to issue up to 150,000 ordinary shares. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code of 1986. Under the ESPP, employees are eligible to purchase ordinary shares through payroll deductions, subject to any plan limitations. The purchase price of the shares on each purchase date is equal to 85% of the lower of the closing market price on the offering date or the closing market price on the purchase date of each three-month offering period. During the year ended December 31, 2021, 4,724 shares have been issued (December 31, 2020: 6,181 and December 31, 2019: 9,202). As of December 31, 2021, a total of 127,302 ordinary shares remains available for issuance under the ESPP plan.

Expenses by nature

Expenses by nature	12 Months Ended
Expenses by nature	Dec. 31, 2021
Expenses by nature
Expenses by nature	13. Expenses by nature Operating expenses excluding expenses presented in other expenses included the following expenses by nature: Years ended December 31, 2021 2020 2019 (in thousands) Employee-related expenses $ 96,161 $ 75,926 $ 59,130 Laboratory and development expenses 36,014 35,977 30,130 Legal and advisory expenses 24,767 17,370 11,297 Office and housing expenses 14,638 13,388 10,588 Other operating expenses 10,528 8,772 8,813 Depreciation and amortization expenses 7,299 10,648 6,669 Fair value loss - Corlieve contingent consideration 6,683 - - Patent and license expenses 3,748 2,899 1,654 Total $ 199,838 $ 164,980 $ 128,281 Details of employee-related expenses for the years ended December 31 are as follows: Years ended December 31, 2021 2020 2019 (in thousands) Wages and salaries $ 53,078 $ 40,919 $ 32,029 Share-based compensation expenses 25,635 21,831 17,533 Other employee expenses 4,570 2,635 1,392 Social security costs 4,496 4,068 2,727 Contractor expenses 3,170 2,423 2,464 Health insurance 3,161 2,271 1,933 Pension costs - defined contribution plans 2,051 1,779 1,052 Total $ 96,161 $ 75,926 $ 59,130

Other income

Other income	12 Months Ended
Other income	Dec. 31, 2021
Other income.
Other income	14. Other income Other income during the year ended December 31, 2021 was $12.3 million compared to $3.3 million and $1.9 million during the same periods in 2020 and 2019, respectively. Other income in 2021, 2020 and 2019 includes income from payments received from European authorities to subsidize the Company’s research and development efforts in the Netherlands. The amount recognized in the year ended December 31, 2021 was $5.3 million compared to $1.9 million in 2020 and $0.7 million in 2019. In addition, other income includes $2.6 million of employee retention credits received under the U.S. Coronavirus Aid, Relief, and Economic Security Act, during the year ended December 31, 2021. An additional $3.0 million of other income was recorded in the year ended December 31, 2021, related to the receipt by the Company of 69,899 shares of VectorY B.V. in conjunction with a settlement agreement that the Company and VectorY B.V. entered into in April 2021. No such income was recorded in 2020 and 2019. In 2021, 2020 and 2019 the Company’s other income also consisted of income from the subleasing of a portion of the Amsterdam facility while other expense consists of expenses incurred in relation to the subleasing income.

Income taxes

Income taxes	12 Months Ended
Income taxes	Dec. 31, 2021
Income taxes
Income taxes	15. Income taxes a. Income tax expense / (benefit) Due to the uncertainty surrounding the realization of favorable tax attributes in future tax returns, the Company has recorded a valuation allowance against the Company’s net deferred tax assets in the Netherlands. The Company released full valuation allowance against the Company’s net deferred tax assets in the United States as of December 31, 2020. In connection with the Corlieve acquisition, the Company recognized a deferred tax liability related to acquired identifiable intangible assets and a deferred tax asset for net operating tax loss carryforwards for a net of EUR 11.9 million ($14.2 million) as of the Acquisition Date. There are no significant unrecognized tax benefits as of December 31, 2021 and 2020. For the years ended December 31, 2021, 2020 and 2019, income / (loss) before income tax (expense) / benefit consists of the following: Years ended December 31, 2021 2020 2019 (in thousands) Dutch operations $ 348,400 $ (130,493) $ (111,820) U.S. operations (12,737) (10,950) (12,381) Other (2,857) — — Total $ 332,806 $ (141,443) $ (124,201) The income tax benefit / (expense) for the years ended December 31, 2021, 2020 and 2019, consists of the following: Years ended December 31, 2021 2020 2019 (in thousands) Current tax (expense) Other $ (7) $ — $ — Total current tax (expense) $ (7) $ — $ — Deferred tax (expense) / benefit Dutch operations $ (3,047) $ — $ — U.S. operations (771) 16,419 — Other 608 — — Total deferred tax (expense) / benefit $ (3,210) $ 16,419 $ — Total income tax (expense) / benefit $ (3,217) $ 16,419 $ — b. Tax rate reconciliation The reconciliation of the amount of income tax (expense) / benefit that would result from applying the Dutch statutory income tax rate to the Company’s reported amount of income tax (expense) / benefit for the years ended December 31, 2021, 2020 and 2019, is as follows: Years ended December 31, 2021 2020 2019 (in thousands) Income / (loss) before income tax (expense) / benefit for the period $ 332,806 $ (141,443) $ (124,201) Expected income tax (expense) / benefit at the tax rate enacted in the Netherlands (25%) (83,201) 35,361 31,050 Non-deductible expenses (9,182) (5,041) (4,972) Other net change in valuation allowance 88,857 (30,568) (25,583) Difference in tax rates between the Netherlands and the U.S. as well as other foreign countries 309 247 (495) Release of valuation allowance related to expected future taxable income of U.S. operations — 16,419 — Income tax (expense) / benefit $ (3,217) $ 16,419 $ — Non-deductible expenses predominantly relate to share-based compensation expenses and affected the effective tax rate by an amount of $6.7 million in 2021 (2020: $5.8 million; 2019: $4.4 million). The fair value loss on contingent consideration affected the effective tax rate by an amount of $2.0 million in 2021 (nil in 2020 and 2019). c. The tax effects of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and deferred tax liabilities as of December 31, 2021 and 2020 are as follows: Years ended December 31, 2021 2020 (in thousands) Deferred tax assets: Net operating loss carryforwards $ 71,917 $ 158,614 Operating lease liabilities 9,300 9,515 Intangible assets 2,039 1,702 Accrued expenses and other current liabilities 1,312 1,118 Property, plant and equipment 971 1,072 Inventory 148 — Research and development tax credit carryforwards 105 - Interest carryforwards — 1,597 Derivative financial instrument — 661 Total deferred tax assets $ 85,792 $ 174,279 Less valuation allowance (60,289) (150,113) Deferred tax assets, net of valuation allowance $ 25,503 $ 24,166 Acquired IPR&D Intangible Asset (see Note 3, "Corlieve transaction") (15,189) — Operating lease right-of-use assets (7,493) (7,702) Other current assets and receivables (87) (45) Deferred tax liability $ (22,769) $ (7,747) Net deferred tax asset $ 2,734 $ 16,419 Changes in the valuation allowance were as follows: Years ended December 31, 2021 2020 2019 (in thousands) January 1, $ 150,113 $ 109,856 $ 85,100 Changes recorded in the statement of operations (88,858) 30,568 25,583 Increase related to 2021, 2020 and 2019 Dutch tax reforms 1,897 18,287 4,059 Valuation allowance assumed in Corlieve acquisition 545 — — Release of valuation allowance related to expected current year and future periods recorded in profit and loss — (16,419) — Other changes including currency translation adjustments (3,408) 7,821 (4,886) December 31, $ 60,289 $ 150,113 $ 109,856 The Company released the full valuation allowance against the Company’s net deferred assets in the United States as of December 31, 2020. Included within changes recorded in the statement of operations for the year ended December 31, 2020 and December 31, 2019 are benefits of $1.2 million and $0.8 million, respectively, from the utilization of U.S. net operating loss carryforwards. The valuation allowance as of December 31, 2021 is primarily related to net operating loss carryforwards in the Netherlands that, in the judgment of management, are not more-likely than-not to be realized. Management considered reversing taxable temporary differences, projected future taxable income and tax-planning strategies in making this assessment. A valuation allowance was recorded against deferred tax assets if it is more likely than not that some or all the deferred tax assets will not be realized. Netherlands As of December 31, 2020, the Company had recorded a full valuation allowance against its Dutch net deferred tax assets. On May 6, 2021, the CSL Behring Agreement became effective (refer to Note 4 “Collaboration arrangements and concentration of credit risk” A portion of the valuation allowance for deferred tax assets relates to follow-on offering costs incurred in 2019 and costs related to the at-the-market offering in 2021. Any subsequently recognized tax benefits will be credited directly to contributed capital. As of December 31, 2021, that amount was $4.5 million ($7.7 million as of December 31, 2020). The Dutch corporate tax rate for fiscal years 2019, 2020 and 2021 was 25%. During 2019, the Dutch government enacted various changes to the corporate income tax rate applicable to future fiscal years. In September 2020, further changes were enacted that retain the corporate income tax rate at 25% from 2021 onwards. In December 2021, even further changes were enacted that raised the corporate income tax rate from 25% to 25.8% from 2022 onwards. A tax reform in December 2018 limited the carryforward of tax losses arising from January 1, 2019, to six years after the end of the respective period. Tax losses incurred prior to this date continue to expire nine years after the end of the respective period. In June 2021 legislation was enacted allowing for an indefinite carryforward from fiscal year 2022 onwards of existing and future net operating loss carryforwards subject to a limit of offsetting taxable profit in excess of EUR 1.0 million to 50% of the taxable profit. The Dutch fiscal unity as of December 31, 2021 has an estimated $228.5 million (2020: $588.2 million; 2019: $414.0 million) of taxable losses that are available for carry forward indefinitely. In the year ended December 31, 2019, unused tax losses of $20.7 million expired. The fiscal periods from 2019 onwards are still open for inspection by the Dutch tax authorities. United States of America The federal corporate tax rate in the U.S. is 21%. In addition, the Company is subject to state income taxes resulting in a combined tax rate of 27.32% for its U.S. operation. As of December 31, 2021, an estimated $39.1 million of net operating losses remain to be carried forward. These losses will expire between 2035 and 2037. The Company’s U.S. operations generated taxable income in the fiscal years 2018 to 2021. Based on the current design of the Company’s worldwide operations, the Company expects to continue to generate taxable income in the U.S. during the foreseeable future. Under the provision of the Internal Revenue Code, the U.S. net operating losses may become subject to an annual limitation in the event of certain cumulative exchange in the ownership interest of significant shareholders over a three-year period in excess of 50 percent, as defined under Section 382 and 383 of the Internal Revenue Code. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation. The fiscal periods from 2018 are still open for inspection by the Internal Revenue Service (“IRS”). To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or Massachusetts Department of Revenue to the extent utilized in a future period. The Company is currently not under examination by the IRS for any tax years. France The French corporate tax rate for fiscal years 2021 was 26.5%, as of January 1, 2022 the tax rate is decreased to 25%. The Company’s French operation has incurred losses since incorporation and is expected to continue incurring tax losses for the foreseeable future. The French operation as of December 31, 2021 has an estimated $9.1 million of taxable losses that are available for carry forward indefinitely.

Basic and diluted earnings per

Basic and diluted earnings per share	12 Months Ended
Basic and diluted earnings per share	Dec. 31, 2021
Basic and diluted earnings per share
Basic and diluted earnings per share	16. Basic and diluted earnings per share Basic net income / (loss) per ordinary share is computed by dividing net income / (loss) for the period by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per ordinary share are calculated by adjusting the weighted average number of ordinary shares outstanding, assuming conversion of all potentially dilutive ordinary shares. For the year ended December 31, 2021, dilutive net income / (loss) per ordinary share is computed using the treasury method. As the Company has incurred a loss in the years ended December 31, 2020 and December 31, 2019, all potentially dilutive ordinary shares for these years would have an antidilutive effect, if converted, and thus have been excluded from the computation of loss per share for the years ended December 31, 2020 and December 31, 2019. Year ended December 31, 2021 2020 2019 (in thousands) Numerator: Net income / (loss) attributable to ordinary shares $ 329,589 $ (125,024) $ (124,201) 329,589 (125,024) Denominator: Weighted-average number of ordinary shares outstanding - basic 45,986,467 44,466,365 39,999,450 Stock options under 2014 Plans and previous plan 746,044 — — Non-vested RSUs and PSUs 107,162 — — Employee share purchase plan 1,299 — — Weighted-average number of ordinary shares outstanding - diluted 46,840,972 44,466,365 39,999,450 The following table presents ordinary share equivalents that were excluded from the calculation of diluted net income / (loss) per ordinary share for the years ended December 31, 2021, 2020 and 2019 as the effect of their inclusion would have been anti-dilutive: Year ended December 31, 2021 2020 2019 (in thousands) Anti-dilutive ordinary share equivalents Stock options under 2014 Plans and previous plan 2,576,281 2,673,279 2,697,104 Non-vested RSUs and PSUs 1,236,385 679,958 850,252 Employee share purchase plan 1,842 560 485 BMS warrants (derecognized as of December 1, 2020 - refer to Note 5, "Fair value measurement" — — 8,893,000 Total anti-dilutive ordinary share equivalents 3,814,508 3,353,797 12,440,841 The anti-dilutive ordinary shares are presented without giving effect to the application of the treasury method or exercise prices that exceeded the price of the Company’s ordinary shares as of December 31, 2020 and December 31, 2019. In addition, the BMS warrants were not exercisable as of December 31, 2019, since this would have required the prior designation of Collaboration Targets by BMS. This would have resulted in a lower number of potentially dilutive ordinary shares as some stock option grants as well as the BMS warrants would have been excluded.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
Commitments and contingencies	Dec. 31, 2021
Commitments and contingencies
Commitments and contingencies	17. In the course of its business, the Company enters as a licensee into contracts with other parties regarding the development and marketing of its pipeline products. Among other payment obligations, the Company is obligated to pay royalties to the licensors based on future sales levels and milestone payments whenever specified development, regulatory and commercial milestones are met. As both future sales levels and the timing and achievement of milestones are uncertain, the financial effect of these agreements cannot be estimated reliably. The Company also has obligations to make future payments that become due and payable upon the collection of milestone payments from CSL Behring. The achievement and timing of these milestones is not fixed and determinable. Relevant commitments and contingencies are further discussed in other sections of this form 10-K, such as, Corlieve transaction and Note 4 “ Collaboration arrangements and concentration of credit risk ”, amongst others.

Related party transaction

Related party transaction	12 Months Ended
Related party transaction	Dec. 31, 2021
Related party transaction
Related party transaction	18. Related party transaction Between June 2015 and December 2020, BMS was considered a related party due to the combination of its equity investment in the Company, the warrants as well as the potential obligations arising from the expansion of collaboration targets. On December 1, 2020, the Company entered into the amended BMS CLA. All transactions subsequent to the effective date of the amended BMS CLA are considered to no longer be with a related party due to the elimination of the potential obligations related to additional Collaboration Targets (see Note 4 “Collaboration arrangements and concentration of credit risk” “Fair value measurement” On October 21, 2021, the Company held an Extraordinary General Meeting of its shareholders and Rachelle Jacques was appointed to the Board of Directors (the “Board”) as a non-executive director. Ms. Jacques will also serve as a member of the Audit Committee of the Board effective as of October 21, 2021. On June 16, 2021, the Company’s shareholders voted to approve the reappointment of Mr. David Meek and Ms. Paula Soteropoulos as non-executive directors of the Board. Mr. Meek has been appointed chairman of the Board. Mr. Philip Astley-Sparke did not stand for reappointment and retired from the Board on June 16, 2021. On June 15, 2021, Christian Klemt was appointed as Chief Financial Officer. Mr. Klemt was our Chief Accounting Officer from August 2017 to June 2021, and he will continue to serve as general manager of our Amsterdam site. Matthew Kapusta, who has been our Chief Executive Officer since December 2016 and had been our Chief Financial Officer from January 2015 to June 2021, will continue to serve as our Chief Executive Officer. In connection with his transition to Chief Financial Officer, Mr. Klemt will also serve as our Principal Financial Officer. On May 17, 2021, Pierre Caloz was appointed as Chief Operating Officer. Mr. Caloz oversees all manufacturing operations, global CMC development and innovation, supply chain, and facilities. On September 14, 2020, the Company appointed Ricardo Dolmetsch, Ph.D. as President, Research and Development. Dr. Dolmetsch succeeded Sander van Deventer, M.D., Ph.D., the former Executive Vice President, Research and Product Development. On August 25, 2020, the Company entered into a separation agreement with Robert Gut, M.D., Ph.D., pursuant to which Dr. Gut transitioned from his role as Chief Medical Officer on October 14, 2020, to be appointed a non-executive director of the Board of Directors. On December 1, 2020, at an extraordinary general meeting, the Company’s shareholders voted to approve the appointment of Dr. Gut as a non-executive director on the Board of Directors. Dr. Gut had previously been appointed as a non-executive director on the Board of Directors on June 13, 2018 by the Company’s shareholders and had resigned as a non-executive director on August 20, 2018, to be appointed as the Company’s Chief Medical Officer. On October 24, 2018, at an extraordinary general meeting, the Company’s shareholders voted to approve the appointment of Dr. Gut as an executive director on the Board of Directors. On June 17, 2020, the Company’s shareholders voted to approve the appointment of Leonard E. Post, Ph.D., as a non-executive director of the Board of Directors. Dr. Post replaced Dr. David Schaffer, whose term as a non-executive director of the Board of Directors ended on the same date. Dr. Post has also assumed the role of chair of the Company’s Research and Development Committee of the Board of Directors.

Subsequent events

Subsequent events	12 Months Ended
Subsequent events	Dec. 31, 2021
Subsequent events
Subsequent events	19. Subsequent events None.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
Summary of significant accounting policies (Policies)	Dec. 31, 2021
Summary of significant accounting policies
Basis of preparation	2.1 Basis of preparation The Company prepared its consolidated financial statements in compliance with generally accepted accounting principles in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The consolidated financial statements have been prepared under the historical cost convention, except for derivative financial instruments and contingent consideration, which are recorded at fair value through profit or loss. The consolidated financial statements are presented in U.S. dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parenthesis, converted at the foreign exchange rate as of the transaction date. The consolidated financial statements presented have been prepared on a going concern basis based on the Company’s cash and cash equivalents as of December 31, 2021 and the Company’s budgeted cash flows for the twelve months following the issuance date.
Use of estimates	2.2 The preparation of consolidated financial statements, in conformity with U.S. GAAP and Securities and Exchange Commission (“SEC”) rules and regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to the treatment of the share and purchase agreement (“SPA”) entered into on June 21, 2021 to acquire all of the outstanding ordinary shares of Corlieve Therapeutics SAS (“Corlieve”), a privately held French gene therapy company (“Corlieve Transaction”), the treatment of the commercialization and license agreement entered into (“CSL Behring Agreement”) between the Company and CSL Behring LLC (“CSL Behring”), the assessment of a valuation allowance on the Company’s deferred tax assets in the Netherlands and the U.S., and the December 1, 2020, amendment (“amended BMS CLA”) of the 2015 collaboration and license agreement (“BMS CLA”) between the Company and Bristol-Myers Squibb (“BMS”). If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.
Accounting policies	2.3 The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Consolidation	2.3.1 The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. Subsidiaries are all entities over which the Company has a controlling financial interest either through variable interest or through voting interest. Currently, the Company has no involvement with variable interest entities. Inter-company transactions, balances, income, and expenses on transactions between uniQure entities are eliminated in consolidation. Profits and losses resulting from inter-company transactions that are recognized in assets are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company.
Current versus non-current classification	2.3.2 The Company presents assets and liabilities in the consolidated balance sheets based on current and non-current classification. The term current assets is used to designate cash and other assets, or resources commonly identified as those that are reasonably expected to be realized in cash or sold or consumed during the normal operating cycle of the business. The Company’s normal operating cycle is twelve months. All other assets are classified as non-current. The term current liabilities is used principally to designate obligations whose liquidation is reasonably expected to require the use of existing resources properly classifiable as current assets, or the creation of other current liabilities. Current liabilities are expected to be settled in the normal operating cycle. The Company classifies all other liabilities as non-current. Deferred tax assets and liabilities are classified as non-current assets and liabilities, if any.
Foreign currency translation	2.3.3 The functional currency of the Company and each of its entities (except for uniQure Inc. and Corlieve AG) is the euro (€). This represents the currency of the primary economic environment in which the entities operate. The functional currency of uniQure Inc. is the U.S. dollar ($) and the functional currency of Corlieve AG is the Swiss Franc. The consolidated financial statements are presented in U.S. dollars. Foreign currency transactions are measured and recorded in the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies at exchange rates prevailing at balance sheet date are recognized in profit and loss. Upon consolidation, the assets and liabilities of foreign operations are translated into the functional currency of the shareholding entity at the exchange rates prevailing at the balance sheet date; items of income and expense are translated at monthly average exchange rates. The consolidated assets and liabilities are translated from uniQure N.V.’s functional currency, euro, into the reporting currency U.S. dollar at the exchange rates prevailing at the balance sheet date; items of income and expense are translated at monthly average exchange rates. Issued capital and additional paid-in capital are translated at historical rates with differences to the balance sheet date rate recorded as translation adjustments in other comprehensive income / loss. The exchange differences arising on translation for consolidation are recognized in “accumulated other comprehensive income / loss”. On disposal of a foreign operation, the component of other comprehensive income / loss relating to that foreign operation is recognized in profit or loss.
Fair value measurement	2.3.4 The Company measures certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. ASC 820, Fair Value Measurements and Disclosures ● Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities in markets that are not active or models for which the inputs are observable, either directly or indirectly. ● Level 3 - Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and are unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Items measured at fair value on a recurring basis include financial instruments and contingent consideration (Note 5, “ Fair value measurement
Corlieve transaction	2.3.5 Corlieve transaction On July 30, 2021 (“Acquisition Date”), the Company acquired Corlieve. The Company evaluated the Corlieve transaction as to whether or not the transaction should be accounted for as a business combination or asset acquisition. Refer to Note 3 “ Corlieve transaction a. Goodwill Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the net assets assumed in a business combination. Goodwill is not amortized but is evaluated for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would more likely than not reduce the fair value of the reporting unit below its carrying amount. As of December 31, 2021, the Company has not recognized any impairment charges related to goodwill. Refer to Note 3 “ Corlieve transaction b. Acquired research and development The Company identified various licenses that combined with the results of the research and development activities conducted in relation to AMT-260 since incorporation of Corlieve in 2019 constitute an In-process research and development intangible asset (“IPR&D Intangible Asset”). The IPR&D Intangible Asset is considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and is not amortized. If and when development is completed, which generally occurs when regulatory approval to market a product is obtained, the associated asset would be deemed finite-lived and would then be amortized based on its respective useful life at that point in time. As of December 31, 2021, the Company has not recognized any impairment charges related to the IPR&D Intangible Asset. In case of abandonment, the IPR&D Intangible Asset will be written-off. In accordance with ASC 350, Intangibles – Goodwill and Other, the Company tests indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair value of the IPR&D Intangible Asset is below its carrying amount. Refer to Note 3 “ Corlieve transaction c. Contingent consideration Each reporting period, the Company revalues the contingent consideration obligations associated with the Corlieve transaction to their fair value and records changes in the fair value within research and development expenses. Changes in contingent consideration result from changes in assumptions regarding the probabilities of achieving the relevant milestones, or probability of success (“POS”), the estimated timing of achieving such milestones, and the interest rate to discount the payments. Payments made soon after the acquisition date are recorded as cash flows from financing activities, and payments, or the portion of the payments, not made soon after the acquisition date are recorded as cash flows from operating activities. Refer to Note 3 “ Corlieve transaction
Notes to the consolidated statements of cash flows	2.3.6 The consolidated statements of cash flows have been prepared using the indirect method. The cash disclosed in the consolidated statements of cash flows is comprised of cash and cash equivalents. Cash and cash equivalents include bank balances, demand deposits and other short-term highly liquid investments (with maturities of less than three months at the time of purchase) that are readily convertible into a known amount of cash and are subject to an insignificant risk of fluctuation in value. Cash flows denominated in foreign currencies have been translated at the average exchange rates. Exchange differences, if any, affecting cash and cash equivalents are shown separately in the consolidated statements of cash flows. Interest paid and received, and income taxes are included in net cash (used in) provided by operating activities.
Segment information	2.3.7 Operating segments are identified as a component of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment, which comprises the discovery, development, and commercialization of innovative gene therapies.
Net income / (loss) per share	2.3.8 The Company follows the provisions of ASC 260, Earnings Per Share Diluted net income / (loss) per share reflects the dilution that would occur if share options or warrants to issue ordinary shares were exercised, performance or restricted share units were distributed, or shares under the employee share purchase plan were issued. However, potential ordinary shares are excluded if their effect is anti-dilutive. Refer to Note 16 “ Basic and diluted earnings per share
Impairment of long-lived assets	2.3.9 Long-lived assets, which include property, plant, and equipment and finite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. Right-of-use assets are also reviewed for impairment in accordance with ASC 360, Property, Plant, and Equipment Refer to Note 2.3.5 “ Corlieve transaction
Property, plant, and equipment	2.3.10 Property, plant, and equipment is comprised mainly of laboratory equipment, leasehold improvements, construction-in-progress (“CIP”) and office equipment. All property, plant and equipment is stated at cost less accumulated depreciation. CIP consists of capitalized expenses associated with construction of assets not yet placed into service. Depreciation commences on CIP once the asset is placed into service based on its useful life determined at that time. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss on the transaction is recognized in the consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets (or in the case of leasehold improvements a shorter lease term), which are as follows: · Between 10 – 15 years · 5 years · Between 3 – 5 years
Leases	2.3.11 The Company adopted ASC 842, Leases The Company measured lease liabilities at the present value of the future lease payments as of January 1, 2019. The Company used an incremental borrowing rate to discount the lease payments. The Company derived the discount rate, adjusted for differences such as in the term and payment patterns, from the Company’s loan from Hercules Technology Growth Capital, Inc (“Hercules Capital”), which was refinanced immediately prior to the January 1, 2019 adoption date in December 2018. The right-of-use asset is valued at the amount of the lease liability reduced by the remaining December 31, 2018 balance of lease incentives received. The lease liability is subsequently measured at the present value of the future lease payments as of the reporting date with a corresponding adjustment to the right-to-use asset. Absent a lease modification, the Company will continue to utilize the January 1, 2019, incremental borrowing rate. For leases recognized after the adoption date, the Company determines if an arrangement is a lease at inception. Operating lease right-of-use assets and lease liabilities are initially recognized based on the present value of future minimum lease payments over the lease term at commencement date calculated using an incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily available. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of twelve months or less are not recognized on the consolidated balance sheets.
Other (non) current assets	2.3.12 Deposits paid are either presented as other current assets or as other non-current assets based on duration of the underlying contractual arrangement. Deposits are classified as restricted cash and primarily relate to facility leases. Contract assets are presented in other current assets or as other non-current assets based on the timing of the right to consideration.
Prepaid expenses	2.3.13 Prepaid expenses are amounts paid in the period, for which the benefit has not been realized, and include payments made for insurance and research and clinical contracts. The related expense will be recognized in the subsequent period as incurred.
Accounts receivable	2.3.14
Accounts payable and accrued expenses	2.3.15 Accounts payables are invoiced amounts related to obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payables are recognized at the amounts invoiced by suppliers. Accrued expenses are recognized for goods or services that have been acquired in the ordinary course of business. Contract liabilities are presented in accounts payable and accrued expenses.
Long-term debt	2.3.16 Long-term debt is initially recognized at cost and presented net of original issue discount or premium and debt issuance costs on the consolidated balance sheets. Amortization of debt discount and debt issuance costs is recognized as interest expense in profit and loss over the period of the debt, using the effective interest rate method.
Pensions and other post-retirement benefit plans	2.3.17 Pensions and other post-retirement benefit plans The Company has a defined contribution pension plan for all employees at its Amsterdam facility in the Netherlands, which is funded by the Company through payments to an insurance company, with individual accounts for each participants’ assets. The Company has no legal or constructive obligation to pay further contributions if the plan does not hold sufficient assets to pay all employees the benefits relating to services rendered in the current and prior periods. The contributions are expensed as incurred. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. In 2016, the Company adopted a qualified 401(k) Plan for all employees located in the United States. The 401(k) Plan offers both a pre-tax and post-tax (Roth) component. Employees may contribute up to the IRS statutory limit each calendar year. The Company matches $0.50 for every $1.00 contributed to the plan by participants up to 6% of base compensation. Employer contributions are recognized as they are contributed, as long as the employee is rendering services in that period. If employer contributions are made in periods after an individual retires or terminates, the estimated cost is accrued during the employee’s service period.
Share-based compensation	2.3.18 The Company accounts for its share-based compensation awards in accordance with ASC 718, Compensation-Stock Compensation. All the Company’s share-based compensation plans for employees are equity-classified. ASC 718 requires all share-based compensation to employees, including grants of employee options, restricted share units, performance share units and modifications to existing instruments, to be recognized in the consolidated statements of operations and comprehensive loss based on their grant-date fair values, net of an estimated forfeiture rate, over the requisite service period. Forfeitures of employee options are recognized as they occur. Compensation expense related to Performance Share Units is recognized when the Company considers achievement of the milestones to be probable. The requirements of ASC 718 are also applied to nonemployee share-based payment transactions except for specific guidance on certain inputs to an option-pricing model and the attribution of cost. The Company uses a Hull & White option model to determine the fair value of option awards. The model captures early exercises by assuming that the likelihood of exercises will increase when the share-price reaches defined multiples of the strike price. This analysis is performed over the full contractual term.
Revenue recognition	2.3.19 Revenue recognition The Company primarily generates revenue from its commercialization and license agreement with CSL Behring and its collaboration, research, and license agreements with BMS for the development and commercialization of product candidates. CSL Behring collaboration On June 24, 2021 (“Signing Date”), the Company entered into a commercialization and license agreement pursuant to which CSL Behring received exclusive global rights to etranacogene dezaparvovec (“Product”). The Company concluded that CSL Behring is a customer in accordance with ASC 606, Revenue from Contracts with Customers (i) Sale of the exclusive global rights to the Product (“License Sale”); and (ii) Generate information to support the regulatory approval of the current and next generation manufacturing process of Product and to provide any such information generated to CSL Behring (“Manufacturing Development”). These performance obligations are considered distinct from one another, as CSL Behring can benefit from the identified service either on its own or together with other resources that are readily available to CSL Behring, and as the performance obligations are separately identifiable from other performance obligations in the CSL Behring Agreement. Refer to Note 4 “ Collaboration arrangements and concentration of credit risk Bristol-Myers Squib collaboration The Company initially entered into collaboration, research, and license agreements with BMS in 2015 and amended them in 2020. The Company evaluated the initial BMS CLA and determined that its performance obligations were as follows: ● Providing pre-clinical research activities (“Collaboration Revenue”); ● Providing clinical and commercial manufacturing services for products (“Manufacturing Revenue”); and ● Providing access to its technology and know-how in the field of gene therapy as well as actively contributing to the target selection, the collaboration as a whole, the development during the target selection, the pre-clinical and the clinical phase through participating in joint steering committee and other governing bodies (“License Revenue”). As further discussed in Note 4, “ Collaboration arrangements and concentration of credit risk License Revenue Until the December 2020 amendment of the BMS CLA the Company recognized License Revenue over the expected performance period based on its measure of progress towards the completion of certain activities related to its services. Following the December 2020 amendment of the BMS CLA the Company’s performance was materially completed and it had satisfied its performance obligation (see Note 4, “Collaboration arrangements and concentration of credit risk” Collaboration and Manufacturing Revenue The Company recognizes Collaboration Revenues associated with optional work orders it receives from BMS to provide analytical development and process development activities that are reimbursable by BMS in accordance with the BMS CLA as well as the amended BMS CLA. BMS and the Company entered into a Master Clinical Supply Agreement in April 2017 for the Company to supply gene therapy products during the clinical phase as well as into a binding term sheet to supply gene therapy products during the commercial phase to BMS. In December 2020, BMS and the Company also entered into a Research Supply Agreement. Revenues from product sales will be recognized when earned. The Company will provide these services as it receives optional work orders from BMS in relation to such services.
Other income, other expense	2.3.20 The Company receives certain government and regional grants, which support its research efforts in defined projects, and include contributions towards the cost of research and development. These grants generally provide for reimbursement of approved costs incurred as defined in the respective grants and are deferred and recognized in the statements of operations and comprehensive loss over the period necessary to match them with the costs they are intended to compensate, when it is probable that the Company has complied with any conditions attached to the grant and will receive the reimbursement. The Company’s other income also consists of employee retention credits received under the U.S. Coronavirus Aid, Relief, and Economic Security Act, income related to a settlement agreement that the Company and VectorY B.V. entered into in April 2021, as well as income from subleasing part of the Company’s Amsterdam facility. Other expense consists of expenses incurred in relation to the subleasing income.
Research and development expenses	2.3.21 Research and development costs are expensed as incurred. Research and development expenses generally consist of laboratory research, clinical trials, statistical analysis, and report writing, regulatory compliance costs incurred with clinical research organizations and other third-party vendors (including post-approval commitments to conduct consistency and comparability studies). In addition, research and development expenses consist of start-up and validation costs related to the Company’s Lexington facility and the development and improvement of the Company’s manufacturing processes and methods. Furthermore, research and development costs include costs of materials and costs of intangible assets purchased from others for use in research and development activities. The costs of intangibles that are purchased from others for a particular research and development project and that have no alternative future uses (in other research and development projects or otherwise) are expensed as research and development costs at the time the costs are incurred or at the time when no alternative future use is identified.
Income taxes	2.3.22 Income taxes are recorded in accordance with ASC 740, Income Taxes The benefits of tax positions are recognized only if those positions are more likely than not, based on the technical merits, to be sustained upon examination. Recognized tax positions are measured at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. The determination as to whether the tax benefit will more-likely-than-not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December 31, 2021, and 2020, the Company did not have any significant unrecognized tax benefits.
Recently Adopted Accounting Pronouncements	2.3.23 Recently Adopted Accounting Pronouncements Recent Accounting Pronouncements Not Yet Effective ASU 2021-10: Government Assistance In November 2018, the FASB issued ASU 2021-10, Government Assistance (Topic 832) which discusses the requirements for disclosures related to transactions with a government. ASU 2021-10 is effective for fiscal years beginning after December 15, 2021. The new disclosure requirements will require disclosures around 1) information about the nature of the transactions and the related accounting policy used to account for the transactions, 2) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, and 3) significant terms and conditions of the transactions, including commitments and contingencies. An entity should apply the updates prospectively or retrospectively. The Company currently includes information on government grants and does not expect these amendments to have a material impact on the Company’s consolidated financial statements.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	12 Months Ended
Summary of significant accounting policies (Tables)	Dec. 31, 2021
Summary of significant accounting policies
Schedule of estimated useful lives of depreciable property, plant and equipment	· Between 10 – 15 years · 5 years · Between 3 – 5 years

Corlieve transaction (Tables)

Corlieve transaction (Tables)	12 Months Ended
Corlieve transaction (Tables)	Dec. 31, 2021
Corlieve transaction
Schedule of provisional fair values assigned to the contingent consideration	Allocation € (in thousands) Consideration Cash € 44,876 Contingent consideration 20,165 Liability related to Mandatorily Redeemable Shares (see below) 719 Fair value of total consideration € 65,760 Recognized amounts of identifiable assets acquired and liabilities assumed Current assets including € € 2,902 Property, plant and equipment 34 Identifiable intangible asset 53,564 Current liabilities (1,132) Deferred tax liability, net (11,915) Debt (1,352) Other non-current liabilities (260) Fair value of net assets acquired 41,841 Goodwill 23,919 € 65,760

Collaboration arrangements an_2

Collaboration arrangements and concentration of credit risk (Tables)	12 Months Ended
	Dec. 31, 2021
Collaboration arrangements and concentration of credit risk
Schedule of collaboration and license revenue	Years ended December 31, 2021 2020 2019 (in thousands) Bristol Myers Squibb $ 4,176 $ 37,514 $ 7,281 $ 4,176 $ 37,514 $ 7,281
Schedule of amounts owed in relation to collaboration	December 31, December 31, 2021 2020 (in thousands) Bristol Myers Squibb $ 914 $ 4,536 Total $ 914 $ 4,536

Fair value measurement and Ot_2

Fair value measurement and Other non-operating (losses) gains (Tables)	12 Months Ended
	Dec. 31, 2021
Fair value measurement and Other non-operating (losses) / gains
Schedule of changes in Level 3 items	Derivative Contingent financial consideration instruments Total (in thousands) Balance at December 31, 2018 $ — $ 1,375 $ 1,375 Net losses recognized in profit or loss — 2,530 2,530 Exercise of Hercules warrants — (770) (770) Currency translation effects — (60) (60) Balance at December 31, 2019 $ — $ 3,075 $ 3,075 Net gains recognized in profit or loss — (2,300) (2,300) Derecognition of BMS warrants — (796) (796) Recognition of derivative financial liability of CoC-payment — 2,613 2,613 Currency translation effects — 53 53 Balance at December 31, 2020 $ — $ 2,645 $ 2,645 Amount recorded for contingent consideration on Acquisition Date of Corlieve 23,950 — 23,950 Net losses recognized in profit or loss 6,683 160 6,843 Currency translation effects (1,091) — (1,091) Balance at December 31, 2021 $ 29,542 $ 2,805 $ 32,347
Schedule of other non-operating (losses) / gains	Years ended December 31, 2021 2020 2019 (in thousands) Other non-operating gains: Derivative gains $ — $ 483 $ — Total other non-operating gains: — 483 — Other non-operating losses: Derivative losses (160) — (2,530) Total other non-operating losses: (160) — (2,530) Other non-operating (losses) / gains, net $ (160) $ 483 $ (2,530)

Property, plant and equipment_2

Property, plant and equipment, net (Tables)	12 Months Ended
Property, plant and equipment, net (Tables)	Dec. 31, 2021
Property, plant and equipment, net
Schedule of property, plant and equipment	December 31, December 31, 2021 2020 (in thousands) Leasehold improvements $ 45,372 $ 37,849 Laboratory equipment 25,499 22,106 Office equipment 4,465 5,025 Construction-in-progress 5,069 2,574 Total property, plant, and equipment 80,405 67,554 Less accumulated depreciation (36,900) (35,226) Property, plant and equipment, net $ 43,505 $ 32,328
Summary of long-lived assets by geographic region	December 31, December 31, 2021 2020 (in thousands) Lexington, Massachusetts (United States of America) $ 17,311 $ 15,949 Amsterdam (the Netherlands) 26,160 16,379 Other 34 - Total $ 43,505 $ 32,328

Right-of-use asset and lease _2

Right-of-use asset and lease liabilities (Tables)	12 Months Ended
Right-of-use asset and lease liabilities (Tables)	Dec. 31, 2021
Right-of-use asset and lease liabilities
Schedule of lease cost, balance sheet and cash flow information	Year ended December 31, 2021 2020 2019 (in thousands) Operating lease cost $ 5,306 $ 5,052 $ 4,474 Variable lease cost 698 607 507 Sublease income (907) (904) (1,053) Total lease cost $ 5,097 $ 4,755 $ 3,928 December 31, December 31, 2021 2020 (in thousands) Assets Operating lease right-of-use assets $ 25,573 26,086 Liabilities Current Current operating lease liabilities 5,774 5,524 Non-current Non-current operating lease liabilities 28,987 30,403 Total lease liabilities $ 34,761 35,927 Year ended December 31, 2021 2020 2019 (in thousands) Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases 1) $ 5,738 $ 5,769 $ 4,717 Right-of-use asset obtained in exchange for lease obligation Operating lease 2) $ 1,699 $ — $ 9,002 1) 2)
Schedule of undiscounted cash flows and minimum lease payments	Lexington Amsterdam (1) Total (in thousands) 2022 $ 3,552 $ 2,222 $ 5,774 2023 3,650 2,668 6,318 2024 4,146 2,112 6,258 2025 4,465 2,112 6,577 2026 4,600 2,112 6,712 Thereafter 11,680 9,736 21,416 Total lease payments $ 32,093 $ 20,962 $ 53,055 Less: amount of lease payments representing interest payments (10,251) (8,043) (18,294) Present value of lease payments 21,842 12,919 34,761 Less: current operating lease liabilities (3,552) (2,222) (5,774) Non-current operating lease liabilities $ 18,290 $ 10,697 $ 28,987 (1) Payments are due in EUR and have been translated at the foreign exchange rate as of December 31, 2021, of $1.13 / €1.00)

Intangible assets, net and Go_2

Intangible assets, net and Goodwill (Tables)	12 Months Ended
Intangible assets, net and Goodwill (Tables)	Dec. 31, 2021
Intangible assets, net and Goodwill
Schedule of acquired licenses and acquired IPR&D intangible asset	December 31, December 31, 2021 2020 (in thousands) Acquired licenses $ 4,755 $ 5,660 Less accumulated amortization (2,827) (2,299) Acquired licenses, net $ 1,928 $ 3,361 Acquired IPR&D Intangible Asset 60,758 — Intangibles, net $ 62,686 $ 3,361
Schedule of estimated future amortization expense	Years Amount (in thousands) 2022 $ 395 2023 133 2024 133 2025 133 2026 133 Thereafter 1,001 Total $ 1,928

Accrued expenses and other cu_2

Accrued expenses and other current liabilities (Tables)	12 Months Ended
Accrued expenses and other current liabilities (Tables)	Dec. 31, 2021
Accrued expenses and other current liabilities
Schedule of accrued expenses and other current liabilities	December 31, December 31, 2021 2020 (in thousands) Accruals for goods received from and services provided by vendors-not yet billed $ 13,012 $ 8,269 Personnel related accruals and liabilities 12,603 7,687 Accrued contract fulfillment costs and costs to obtain a contract 2,872 — Contract liability (see Note 4. "Collaboration arrangements and concentration of credit risk") — 2,082 Total $ 28,487 $ 18,038

Long-term debt (Tables)

Long-term debt (Tables)	12 Months Ended
Long-term debt (Tables)	Dec. 31, 2021
Long-term debt
Schedule of interest expense	Years Amount (in millions) 2021 $ 7.2 2020 3.7 2019 3.7
Schedule of aggregate maturities of the loan	Years Amount (in thousands) 2022 $ 7,984 2023 10,580 2024 15,474 2025 101,549 Total $ 135,587

Share-based compensation (Table

Share-based compensation (Tables)	12 Months Ended
Share-based compensation (Tables)	Dec. 31, 2021
Share-based compensation
Schedule of share-based compensation expense by classification included in consolidated statements of operations and comprehensive loss	Year ended December 31, 2021 2020 2019 (in thousands) Research and development $ 12,813 $ 11,965 $ 8,029 Selling, general and administrative 12,794 9,823 9,439 Total $ 25,607 $ 21,788 $ 17,468
Schedule of share-based compensation expense	Year ended December 31, 2021 2020 2019 (in thousands) Award type Share options $ 12,477 $ 11,434 $ 7,896 Restricted share units 11,347 7,364 4,117 Performance share units 1,783 2,990 5,455 Total $ 25,607 $ 21,788 $ 17,468
Schedule of unrecognized compensation cost related to unvested awards	Unrecognized Weighted average share-based remaining compensation period for expense recognition (in thousands) (in years) Award type Share options $ 29,513 2.79 Restricted share units 19,348 2.00 Performance share units 781 0.63 Total $ 49,642 2.45
Schedule of weighted-average assumptions for fair value of option issued	Year ended December 31, Assumptions 2021 2020 2019 Expected volatility 75% 70% 70% - 75% Expected terms 10 years 10 years 10 years Risk free interest rate 1.21 - 1.86% 0.76% - 1.44% 1.92% - 2.87% Expected dividend yield 0% 0% 0%
Summary of RSUs activity	RSU Weighted average Number of grant-date fair ordinary shares value Non-vested at December 31, 2020 467,344 $ 43.56 Granted 574,921 $ 36.14 Vested (220,518) $ 40.56 Forfeited (111,130) $ 40.98 Non-vested at December 31, 2021 710,617 $ 38.89 Total weighted average grant date fair value of RSUs granted during the period (in $ millions) $ 20.8 Granted to directors and officers during the period (shares, $ in millions) 167,230 $ 6.1
Summary of PSUs activity	PSU Weighted average Number of grant-date fair ordinary shares value Non-vested at December 31, 2020 212,614 $ 42.32 Granted 555,600 30.19 Vested (132,368) $ 33.09 Forfeited (2,916) $ 57.56 Non-vested at December 31, 2021 632,930 $ 33.54 Total weighted average grant date fair value of PSUs granted during the period (in $ millions) $ 16.8
2014 Plan.
Share-based compensation
Summary of option activity	Options Number of Weighted average Weighted average Aggregate intrinsic ordinary shares exercise price remaining contractual life value in years (in thousands) Outstanding at December 31, 2020 2,659,279 $ 28.13 7.18 $ 32,729 Granted 1,174,893 $ 35.85 Forfeited (258,718) $ 40.78 Expired (25,633) $ 42.81 Exercised (241,496) $ 10.98 Outstanding at December 31, 2021 3,308,325 $ 31.02 7.05 8,660 Thereof, fully vested and exercisable at December 31, 2021 1,786,825 $ 24.47 5.49 8,640 Thereof, outstanding and expected to vest after December 31, 2021 1,521,500 $ 38.71 8.88 20 Outstanding and expected to vest at December 31, 2020 1,116,874 $ 42.06 Total weighted average grant date fair value of options issued during the period (in $ millions) $ 24.6 Granted to directors and officers during the period (options, grant date fair value $ in millions) 312,704 $ 6.5 Proceeds from option sales during the period (in $ millions) $ 2.7
Summary of information about weighted average grant-date fair value of options granted	Weighted average Options grant ‑ date fair value Granted, 2021 1,174,893 $ 20.95 Granted, 2020 653,852 28.08 Granted, 2019 647,526 23.57 Vested, 2021 507,503 22.17 Forfeited, 2021 (258,718) 23.60
Summary of summarizes information about the weighted average grant-date fair value of options outstanding and expected to vest	Weighted average Options grant ‑ date fair value Outstanding and expected to vest, 2021 1,521,500 $ 22.52 Outstanding and expected to vest, 2020 1,116,874 24.25
Summary of information about options exercised	Exercised during the year Intrinsic value (in thousands) 2021 241,496 $ 5,046 2020 498,678 11,927 2019 434,665 17,700
Restricted share units ("RSUs")
Share-based compensation
Summary of information about weighted average grant-date fair value of options granted	Granted Weighted average during the year grant ‑ date fair value 2021 574,921 $ 36.14 2020 376,799 48.18 2019 198,504 38.63
Summary of information about the total fair value of stock that vested	Total fair value (in thousands) 2021 $ 8,063 2020 12,156 2019 10,152
Performance Share Awards
Share-based compensation
Summary of information about weighted average grant-date fair value of options granted	Granted Weighted average during the year grant ‑ date fair value 2021 555,600 $ 30.19 2020 91,003 $ 57.56 2019 132,362 $ 31.71
Summary of information about the total fair value of stock that vested	Total fair value (in thousands) 2021 $ 5,074 2020 21,852 2019 1,056

Expenses by nature (Tables)

Expenses by nature (Tables)	12 Months Ended
Expenses by nature (Tables)	Dec. 31, 2021
Expenses by nature
Schedule of operating expenses	Years ended December 31, 2021 2020 2019 (in thousands) Employee-related expenses $ 96,161 $ 75,926 $ 59,130 Laboratory and development expenses 36,014 35,977 30,130 Legal and advisory expenses 24,767 17,370 11,297 Office and housing expenses 14,638 13,388 10,588 Other operating expenses 10,528 8,772 8,813 Depreciation and amortization expenses 7,299 10,648 6,669 Fair value loss - Corlieve contingent consideration 6,683 - - Patent and license expenses 3,748 2,899 1,654 Total $ 199,838 $ 164,980 $ 128,281
Schedule of employee-related expenses	Years ended December 31, 2021 2020 2019 (in thousands) Wages and salaries $ 53,078 $ 40,919 $ 32,029 Share-based compensation expenses 25,635 21,831 17,533 Other employee expenses 4,570 2,635 1,392 Social security costs 4,496 4,068 2,727 Contractor expenses 3,170 2,423 2,464 Health insurance 3,161 2,271 1,933 Pension costs - defined contribution plans 2,051 1,779 1,052 Total $ 96,161 $ 75,926 $ 59,130

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
Income taxes (Tables)	Dec. 31, 2021
Income taxes
Schedule of Income / (loss) before income tax (expense) / benefit	Years ended December 31, 2021 2020 2019 (in thousands) Dutch operations $ 348,400 $ (130,493) $ (111,820) U.S. operations (12,737) (10,950) (12,381) Other (2,857) — — Total $ 332,806 $ (141,443) $ (124,201)
Schedule of income tax benefit / (expense)	Years ended December 31, 2021 2020 2019 (in thousands) Current tax (expense) Other $ (7) $ — $ — Total current tax (expense) $ (7) $ — $ — Deferred tax (expense) / benefit Dutch operations $ (3,047) $ — $ — U.S. operations (771) 16,419 — Other 608 — — Total deferred tax (expense) / benefit $ (3,210) $ 16,419 $ — Total income tax (expense) / benefit $ (3,217) $ 16,419 $ —
Schedule of reconciliation of statutory income tax rate to effective tax rate	Years ended December 31, 2021 2020 2019 (in thousands) Income / (loss) before income tax (expense) / benefit for the period $ 332,806 $ (141,443) $ (124,201) Expected income tax (expense) / benefit at the tax rate enacted in the Netherlands (25%) (83,201) 35,361 31,050 Non-deductible expenses (9,182) (5,041) (4,972) Other net change in valuation allowance 88,857 (30,568) (25,583) Difference in tax rates between the Netherlands and the U.S. as well as other foreign countries 309 247 (495) Release of valuation allowance related to expected future taxable income of U.S. operations — 16,419 — Income tax (expense) / benefit $ (3,217) $ 16,419 $ —
Schedule of significant portions of deferred tax assets and deferred tax liabilities	Years ended December 31, 2021 2020 (in thousands) Deferred tax assets: Net operating loss carryforwards $ 71,917 $ 158,614 Operating lease liabilities 9,300 9,515 Intangible assets 2,039 1,702 Accrued expenses and other current liabilities 1,312 1,118 Property, plant and equipment 971 1,072 Inventory 148 — Research and development tax credit carryforwards 105 - Interest carryforwards — 1,597 Derivative financial instrument — 661 Total deferred tax assets $ 85,792 $ 174,279 Less valuation allowance (60,289) (150,113) Deferred tax assets, net of valuation allowance $ 25,503 $ 24,166 Acquired IPR&D Intangible Asset (see Note 3, "Corlieve transaction") (15,189) — Operating lease right-of-use assets (7,493) (7,702) Other current assets and receivables (87) (45) Deferred tax liability $ (22,769) $ (7,747) Net deferred tax asset $ 2,734 $ 16,419
Summary of Changes in the valuation allowance	Years ended December 31, 2021 2020 2019 (in thousands) January 1, $ 150,113 $ 109,856 $ 85,100 Changes recorded in the statement of operations (88,858) 30,568 25,583 Increase related to 2021, 2020 and 2019 Dutch tax reforms 1,897 18,287 4,059 Valuation allowance assumed in Corlieve acquisition 545 — — Release of valuation allowance related to expected current year and future periods recorded in profit and loss — (16,419) — Other changes including currency translation adjustments (3,408) 7,821 (4,886) December 31, $ 60,289 $ 150,113 $ 109,856

Basic and diluted earnings pe_2

Basic and diluted earnings per share (Tables)	12 Months Ended
Basic and diluted earnings per share (Tables)	Dec. 31, 2021
Basic and diluted earnings per share
Schedule of basic and diluted earnings per share	Year ended December 31, 2021 2020 2019 (in thousands) Numerator: Net income / (loss) attributable to ordinary shares $ 329,589 $ (125,024) $ (124,201) 329,589 (125,024) Denominator: Weighted-average number of ordinary shares outstanding - basic 45,986,467 44,466,365 39,999,450 Stock options under 2014 Plans and previous plan 746,044 — — Non-vested RSUs and PSUs 107,162 — — Employee share purchase plan 1,299 — — Weighted-average number of ordinary shares outstanding - diluted 46,840,972 44,466,365 39,999,450
Schedule of potential dilutive common shares	Year ended December 31, 2021 2020 2019 (in thousands) Anti-dilutive ordinary share equivalents Stock options under 2014 Plans and previous plan 2,576,281 2,673,279 2,697,104 Non-vested RSUs and PSUs 1,236,385 679,958 850,252 Employee share purchase plan 1,842 560 485 BMS warrants (derecognized as of December 1, 2020 - refer to Note 5, "Fair value measurement" — — 8,893,000 Total anti-dilutive ordinary share equivalents 3,814,508 3,353,797 12,440,841

Summary of significant accoun_4

Summary of significant accounting policies (Details)	12 Months Ended
Summary of significant accounting policies (Details)	Dec. 31, 2021USD ($)segment$ / shares
Segment information
Number of operating segments \| segment	1
Current and non-current classification
Operating cycle period	12 months
Pension benefits \| Lexington
Pensions
Amount of employer matching contribution for every employee dollar contributed \| $	$ 0.50
Lexington. \| Pension benefits
Pensions
Amount contributed to plan (in dollars per share) \| $ / shares	$ 1
Maximum \| Pension benefits \| Lexington
Pensions
Percent of employee gross pay for which the employer makes a matching contribution	6.00%
Leasehold improvements \| Minimum
Property, plant and equipment, net
Estimated useful life (in years)	10 years
Leasehold improvements \| Maximum
Property, plant and equipment, net
Estimated useful life (in years)	15 years
Laboratory equipment
Property, plant and equipment, net
Estimated useful life (in years)	5 years
Office equipment \| Minimum
Property, plant and equipment, net
Estimated useful life (in years)	3 years
Office equipment \| Maximum
Property, plant and equipment, net
Estimated useful life (in years)	5 years

Corlieve transaction - Provisio

Corlieve transaction - Provisional Fair Values to Contingent Consideration, Assets Acquired and Liabilities Assumed (Details) € in Thousands, $ in Thousands	Jul. 30, 2021EUR (€)	Dec. 31, 2021USD ($)$ / €	Jul. 30, 2021USD ($)	Jul. 30, 2021EUR (€)	Dec. 31, 2020USD ($)
Consideration
Exchange rate (in USD per Euro) \| $ / €		1.13
Recognized amounts of identifiable assets acquired and liabilities assumed
Goodwill \| $		$ 27,633			$ 542
Acquisition of Corlieve
Consideration
Cash	€ 44,876
Contingent consideration				€ 20,165
Liability related to Mandatorily Redeemable Shares			$ 900	719
Fair value of total consideration	65,760
Recognized amounts of identifiable assets acquired and liabilities assumed
Current assets including 2.8 million of cash			3,400	2,902
Property, plant and equipment				34
Identifiable intangible asset				53,564
Current liabilities			(1,300)	(1,132)
Deferred tax liability, net			(14,200)	(11,900)
Debt				(1,352)
Other non-current liabilities				(260)
Fair value of net assets acquired				41,841
Goodwill			28,400	23,919
Business combination, consideration transferred	€ 65,760
Current assets of cash			$ 3,300	€ 2,800
Net loss of Corlieve and its Swiss subsidiary \| $		7,300
Net loss from Corlieve and its Swiss subsidiary included in the consolidated results \| $		$ 4,100

Corlieve transaction - Narrativ

Corlieve transaction - Narrative (Details) € in Thousands, $ in Thousands	Sep. 30, 2021USD ($)	Sep. 30, 2021EUR (€)	Jul. 30, 2021USD ($)employeeInstitution	Jul. 30, 2021EUR (€)	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019	Dec. 31, 2021EUR (€)	Jul. 31, 2021USD ($)	Jul. 31, 2021EUR (€)	Jul. 30, 2021EUR (€)employeeInstitution
Business Acquisition [Line Items]
Contingent consideration							$ 29,542
Enacted tax rate						25.80%	25.00%	25.00%	25.00%
Goodwill							$ 27,633	$ 542
Repayment of debt acquired through acquisition of Corlieve							$ 1,572
Acquisition of Corlieve
Business Acquisition [Line Items]
Number of institutions \| Institution			2										2
Number of employees employed \| employee			7										7
Percentage of outstanding ordinary shares			97.70%				100.00%			100.00%			97.70%
Value of shares issued			$ 53,300	€ 44,900
Amount of liability related to mandatorily redeemable shares			900										€ 719
Contingent consideration			$ 24,000				$ 29,500			€ 26,000			€ 20,200
Percentage of increase in Probability of Success					40.00%		55.00%
Weighted average cost of capital			10.40%										10.40%
Provisional fair value of IPR&D intangible asset			$ 63,600										€ 53,600
Deferred tax assets			1,700										1,500
Intangible assets			$ 15,900								$ 15,900	€ 13,400	13,400
Enacted tax rate			25.00%	25.00%
Deferred tax liability, net			$ 14,200										11,900
Goodwill			28,400										23,919
Repayment of debt acquired through acquisition of Corlieve	$ 1,200	€ 1,000	400	€ 400
Current assets			3,400										2,902
Cash			3,300										2,800
Current liabilities			$ 1,300										€ 1,132
Acquisition of Corlieve \| Maximum
Business Acquisition [Line Items]
Consideration payable in development milestones through phase I or II							$ 40,600			35,800
Consideration payable in development milestones through phase III							$ 162,300			€ 143,100
Percentage of milestones payable through the issuance of shares							25.00%

Collaboration arrangements an_3

Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details) $ in Thousands	May 06, 2021USD ($)	Dec. 17, 2020USD ($)item	Dec. 01, 2020USD ($)item	Nov. 30, 2020USD ($)	Jun. 24, 2020USD ($)	May 21, 2015USD ($)	Aug. 31, 2015USD ($)	Dec. 31, 2022	Dec. 31, 2021USD ($)item	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Collaboration arrangements
Number of collaboration targets \| item			4
Number of additional targets in a collaboration agreement \| item									6
License revenues from related party				$ 27,800
Revenue									$ 524,002	$ 37,514	$ 7,281
Enacted tax rate								25.80%	25.00%	25.00%	25.00%
Income tax benefit of past share issuance cost									$ 3,047
CSL Behring collaboration
Collaboration arrangements
Revenue	$ 462,400								517,400	$ 0	$ 0
Upfront cash to receive upon the closing of the agreement					$ 450,000
Other payments received					12,400
Accounts receivable									2,900	2,100
Contract asset									55,000
Regulatory and commercial milestone payments received					1,600					2,100
Milestone payments to be received upon achievement					$ 55,000
Other Current Assets \| CSL Behring collaboration
Collaboration arrangements
Capitalized Contract Cost, Net										2,100
License revenues from related party
Collaboration arrangements
Revenue									0	32,967	4,988
Collaboration revenues from related party
Collaboration arrangements
Revenue										136	2,293
Collaborative Revenue Including Revenue From Related Party
Collaboration arrangements
Revenue									4,200	200	2,300
Collaboration revenues
Collaboration arrangements
Revenue									$ 6,602	59
BMS arrangement
Collaboration arrangements
Number of collaboration targets \| item									4
Revenue									$ 4,176	37,514	7,281
BMS arrangement \| Second, Third, and Fourth Targets Selection
Collaboration arrangements
Upfront payment recorded						$ 60,100	$ 15,000
BMS arrangement \| CSL Behring collaboration
Collaboration arrangements
Number of collaboration targets \| item			4
Collaboration Agreement, Period From Effective Date Collaboration Targets Can Be Replaced			1 year
Threshold Number Of New Collaboration Targets In The Field Of Cardiovascular Disease \| item			2
BMS arrangement \| Bristol Myers Squibb
Collaboration arrangements
Initial research term									4 years
Number of potential targets included in collaborative agreement \| item									10
Number of collaboration targets \| item		4							4
Collaboration Agreement, Threshold Number Of Collaboration Targets That Can Be Replaced \| item			2
Revenue									$ 4,176	37,514	$ 7,281
BMS arrangement \| Bristol Myers Squibb \| Maximum
Collaboration arrangements
Number of collaboration targets \| item			4
Collaborative revenue \| CSL Behring collaboration
Collaboration arrangements
Revenue									2,400
License revenue \| Bristol Myers Squibb
Collaboration arrangements
Maximum target designation payments to which entitled per agreement									$ (16,500)
Royalty term after the first commercial sale									10 years
Bristol Myers Squibb \| BMS arrangement
Collaboration arrangements
Collaboration Agreement, Threshold Research, Development And Regulatory Milestone Payments Receivable			$ 217,000
Bristol Myers Squibb \| Collaborative revenue
Collaboration arrangements
Upfront cash to receive upon the closing of the agreement		$ 4,400
Bristol Myers Squibb \| License revenue
Collaboration arrangements
Revenue										$ 4,400

Collaboration arrangements an_4

Collaboration arrangements and concentration of credit risk - Amounts owed by BMS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Number of ordinary shares held	46,298,635	44,777,799
Total revenues	$ 524,002	$ 37,514	$ 7,281
BMS arrangement
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Amounts owed in relation to the collaboration services	914	4,536
Total revenues	4,176	37,514	7,281
BMS arrangement \| Bristol Myers Squibb
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Amounts owed in relation to the collaboration services	914	4,536
Total revenues	$ 4,176	$ 37,514	$ 7,281

Fair value measurement and Ot_3

Fair value measurement and Other non-operating (losses) gains - Changes in Level 3 items (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Changes in Level 3 liabilities
Beginning Balance	$ 2,645	$ 3,075	$ 1,375
Amount recorded for contingent consideration on Acquisition Date of Corlieve	23,950
Net (gains) losses recognized in profit or loss	6,843	(2,300)	2,530
Exercise of Hercules warrants			(770)
Derecognition of BMS warrants		(796)
Recognition of derivative financial liability of CoC-payment		(2,613)
Currency translation effects	(1,091)	53	60
Ending Balance	32,347	2,645	3,075
Contingent consideration.
Changes in Level 3 liabilities
Amount recorded for contingent consideration on Acquisition Date of Corlieve	23,950
Net (gains) losses recognized in profit or loss	6,683
Currency translation effects	(1,091)
Ending Balance	29,542
Derivative liabilities
Changes in Level 3 liabilities
Beginning Balance	2,645	3,075	1,375
Net (gains) losses recognized in profit or loss	160	(2,300)	2,530
Exercise of Hercules warrants			(770)
Derecognition of BMS warrants		(796)
Recognition of derivative financial liability of CoC-payment		(2,613)
Currency translation effects		53	60
Ending Balance	$ 2,805	$ 2,645	$ 3,075

Fair value measurement and Ot_4

Fair value measurement and Other non-operating (losses) gains - Derivative financial instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other non-operating gains
Derivative gains		$ 483
Total other non-operating gains:		483
Other non-operating losses
Derivative losses	$ (160)		$ (2,530)
Total other non-operating losses:	(160)		(2,530)
Other non-operating (losses) / gains , net	(160)	483	(2,530)
Gain (Loss) recorded due to changes in fair value of derivative liability	6,843	(2,300)	2,530
CoC-payment \| Other nonoperating (losses) / gains
Other non-operating losses
Gain (Loss) from the recognition of the derivative financial liability		2,600
Recurring Fair Value Measurements \| Fair value hierarchy Level 3 \| Hercules Loan Facility Warrant \| Other nonoperating (losses) / gains
Other non-operating losses
Gain (Loss) recorded due to changes in fair value of derivative liability	$ 0	$ 0	$ (200)

Fair value measurement and Ot_5

Fair value measurement and Other non-operating (losses) gains - BMS warrants - Narrative (Details) $ / shares in Units, $ in Thousands	Dec. 17, 2020item	Dec. 01, 2020USD ($)item	Dec. 31, 2021USD ($)item$ / shares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Apr. 06, 2015$ / shares
Collaboration arrangements
Number of warrant types			2
Number of Collaboration Targets		4
Collaboration Agreement, Cash Payable \| $		$ 70,000
Fair value of derivative financial instruments \| $			$ 32,347	$ 2,645	$ 3,075	$ 1,375
Other nonoperating (losses) / gains \| CoC-payment
Collaboration arrangements
Fair value of the derivative financial liability \| $			200
Gain (Loss) from the recognition of the derivative financial liability \| $				2,600
Non-current liabilities
Collaboration arrangements
Fair value of the derivative financial liability \| $			$ 2,800	2,600
BMS arrangement
Collaboration arrangements
Number of Collaboration Targets			4
BMS arrangement \| Bristol Myers Squibb
Collaboration arrangements
Number of potential targets included in collaborative agreement			10
Number of Collaboration Targets	4		4
BMS arrangement \| Bristol Myers Squibb \| Maximum
Collaboration arrangements
Number of Collaboration Targets		4
BMS Warrants
Collaboration arrangements
Exercise price in respect of each warrant \| $ / shares			$ 57.32				$ 33.84
Number of trading days used to calculate Volume Weighted Average Price ("VWAP")			20 days
Number of days prior to purchase or exercise used to calculate Volume Weighted Average Price ("VWAP")			5 days
Compounded annual growth rate used to determine fair value of exercise price			10.00%
BMS Warrants \| Other nonoperating (losses) / gains \| Fair value hierarchy Level 3
Collaboration arrangements
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings \| $				3,100	(2,300)
BMS Warrants \| BMS arrangement
Collaboration arrangements
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings \| $				$ 800
BMS Warrants \| Recurring Fair Value Measurements
Collaboration arrangements
Derivative Asset \| $					$ 3,100
Collaboration Agreement, If 70 Million Is Greater Than Five Percent Of Net Proceeds \| Derecognition Of Warrants
Collaboration arrangements
Threshold Percentage Of Net Proceeds		5
Percentage Of Net Proceeds Payable		5
Collaboration Agreement, If 70 Million Is Lesser Than One Percent Of Net Proceeds \| Derecognition Of Warrants
Collaboration arrangements
Threshold Percentage Of Net Proceeds		1
Percentage Of Net Proceeds Payable		1
Bristol Myers Squibb \| uniQure N.V. \| First Six New Targets Or Designation Of Sixth Target \| BMS Warrants
Collaboration arrangements
Ownership percentage required per agreement			14.90%
Bristol Myers Squibb \| uniQure N.V. \| First Six New Targets Or Designation Of Sixth Target \| BMS Warrants \| Minimum
Collaboration arrangements
Number of Collaboration Targets			6
Bristol Myers Squibb \| uniQure N.V. \| First Six New Targets Or Designation Of Sixth Target \| BMS Warrants \| Maximum
Collaboration arrangements
Number of Collaboration Targets			7
Bristol Myers Squibb \| uniQure N.V. \| First Nine New Targets Or Designation Of Ninth Target \| BMS Warrants
Collaboration arrangements
Ownership percentage required per agreement			19.90%
Bristol Myers Squibb \| uniQure N.V. \| First Nine New Targets Or Designation Of Ninth Target \| BMS Warrants \| Minimum
Collaboration arrangements
Number of Collaboration Targets			9
Bristol Myers Squibb \| uniQure N.V. \| First Nine New Targets Or Designation Of Ninth Target \| BMS Warrants \| Maximum
Collaboration arrangements
Number of Collaboration Targets			10

Fair value measurement and Ot_6

Fair value measurement and Other non-operating (losses) gains - Hercules loan facility (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 01, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 13, 2019	Sep. 10, 2019
Fair value measurements
Issue price per share					$ 46	$ 46
Proceeds from exercise of warrants				$ 500
Net (gains) losses recognized in profit or loss		$ 6,843	$ (2,300)	2,530
Recurring Fair Value Measurements \| Fair value hierarchy Level 3 \| Hercules Loan Facility Warrant \| Other nonoperating (losses) / gains
Fair value measurements
Net (gains) losses recognized in profit or loss		0	$ 0	$ (200)
Bristol Myers Squibb \| BMS arrangement \| Hercules Warrants
Fair value measurements
Number of shares issued for exercise of warrants	37,175
Issue price per share	$ 34.25
Proceeds from exercise of warrants	$ 500
Contingent consideration.
Fair value measurements
Net (gains) losses recognized in profit or loss		$ 6,683

Fair value measurement and Ot_7

Fair value measurement and Other non-operating (losses) gains - Contingent Consideration (Details) € in Thousands, $ in Thousands	Jul. 30, 2021EUR (€)	Sep. 30, 2021	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2021EUR (€)	Jul. 30, 2021USD ($)	Jul. 30, 2021EUR (€)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration			$ 29,542
Increase in contingent consideration liability \| €				€ 5,000
Non-current liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, consideration transferred			$ 800
One hundred percent likelihood of AMT-260 advancing into clinical development
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Percentage of increase in Probability of Success			100.00%	100.00%
Increase in contingent consideration liability			$ 47,000
Acquisition of Corlieve
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration			$ 29,500		€ 26,000	$ 24,000	€ 20,200
Percentage of increase in Probability of Success		40.00%	55.00%	55.00%
Increase in contingent consideration liability			$ 5,800
Business combination, consideration transferred \| €	€ 65,760
Acquisition of Corlieve \| Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration payable upon achievement of contractually defined milestones			$ 202,800		€ 178,800
Contingent consideration discount rate percentage			11.90%	11.90%
Acquisition of Corlieve \| Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration discount rate percentage			10.90%	10.90%

Property, plant and equipment_3

Property, plant and equipment, net - Summary of PP&E (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, plant and equipment, net
Total property, plant, and equipment	$ 80,405	$ 67,554
Less accumulated depreciation	(36,900)	(35,226)
Property, plant and equipment, net	43,505	32,328
Depreciation	6,100	5,700	$ 6,000
Leasehold improvements
Property, plant and equipment, net
Total property, plant, and equipment	45,372	37,849
Laboratory equipment
Property, plant and equipment, net
Total property, plant, and equipment	25,499	22,106
Office equipment
Property, plant and equipment, net
Total property, plant, and equipment	4,465	5,025
Construction-in-progress
Property, plant and equipment, net
Total property, plant, and equipment	$ 5,069	$ 2,574

Property, plant and equipment_4

Property, plant and equipment, net - PP&E by geographic region (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Long-lived assets
Long-lived assets	$ 43,505	$ 32,328
Lexington.
Long-lived assets
Long-lived assets	17,311	15,949
Amsterdam
Long-lived assets
Long-lived assets	26,160	$ 16,379
Other
Long-lived assets
Long-lived assets	$ 34

Right-of-use asset and lease _3

Right-of-use asset and lease liabilities - Narrative (Details) € in Millions, $ in Millions	1 Months Ended	12 Months Ended
	Nov. 30, 2018ft²item	Dec. 31, 2021USD ($)ft²item	Dec. 31, 2021EUR (€)ft²item	May 31, 2021m²	Dec. 31, 2020	Dec. 31, 2019USD ($)	Dec. 01, 2017	Jun. 30, 2016	Mar. 31, 2016	Nov. 30, 2013
Leases
Area of facility (in square feet)	30,655			1,080
Lease incentives \| $						$ 1.5
Weighted-average remaining lease term, Operating leases		8 years 3 months 18 days	8 years 3 months 18 days		9 years 4 months 24 days
Weighted-average discount rate, Operating leases		11.34%	11.34%		11.37%
Lexington.
Leases
Lease term (in years)	5 years	7 years	7 years							10 years
Area of facility (in square feet) \| ft²		13,501	13,501
Number of subsequent renewals \| item	2	1	1
Renewal term (in years)	5 years	5 years	5 years
Amsterdam
Leases
Lease term (in years)							10 years		16 years
Renewal term (in years)								5 years
Minimum rentals to be received		$ 5.4	€ 4.7

Right-of-use asset and lease _4

Right-of-use asset and lease liabilities - Operating lease liabilities (Details) $ in Thousands	Jan. 01, 2019USD ($)	Dec. 01, 2017floor	Feb. 29, 2020floor	Dec. 31, 2021USD ($)$ / €	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Components of lease cost
Operating lease cost				$ 5,306	$ 5,052	$ 4,474
Variable lease cost				698	607	507
Sublease income				(907)	(904)	(1,053)
Total lease cost				5,097	4,755	3,928
Assets
Operating lease right-of-use assets				25,573	26,086
Right-of-use assets in exchange for lease obligations				1,699		9,002
Current liabilities
Current operating lease liability				5,774	5,524
Non-current liabilities
Non-current operating lease liability				28,987	30,403
Total lease liabilities				$ 34,761	$ 35,927
Weighted-average remaining lease term, Operating leases				8 years 3 months 18 days	9 years 4 months 24 days
Weighted-average discount rate, Operating leases				11.34%	11.37%
Supplemental cash flow information related to leases
Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows for operating leases				$ 5,738	$ 5,769	4,717
Right-of-use asset obtained in exchange for lease obligation
Operating lease				1,699		$ 9,002
Amount capitalized of right-of-use assets	$ 19,000
Undiscounted Cash Flows
2022				5,774
2023				6,318
2024				6,258
2025				6,577
2026				6,712
Thereafter				21,416
Total lease payments				53,055
Less: amount of lease payments representing interest payments				(18,294)
Total lease liabilities				34,761	35,927
Less: current operating lease liabilities				(5,774)	(5,524)
Non-current operating lease liabilities				$ 28,987	$ 30,403
Exchange rate (in USD per Euro) \| $ / €				1.13
Lexington.
Current liabilities
Current operating lease liability				$ 3,552
Non-current liabilities
Non-current operating lease liability				18,290
Total lease liabilities				21,842
Undiscounted Cash Flows
2022				3,552
2023				3,650
2024				4,146
2025				4,465
2026				4,600
Thereafter				11,680
Total lease payments				32,093
Less: amount of lease payments representing interest payments				(10,251)
Total lease liabilities				21,842
Less: current operating lease liabilities				(3,552)
Non-current operating lease liabilities				18,290
Amsterdam
Components of lease cost
Number of floor of the facility \| floor		7
Number of floors to sub-lease \| floor		3
Number of floor to take back from the sub-lease \| floor			1
Current liabilities
Current operating lease liability				2,222
Non-current liabilities
Non-current operating lease liability				10,697
Total lease liabilities				12,919
Undiscounted Cash Flows
2022				2,222
2023				2,668
2024				2,112
2025				2,112
2026				2,112
Thereafter				9,736
Total lease payments				20,962
Less: amount of lease payments representing interest payments				(8,043)
Total lease liabilities				12,919
Less: current operating lease liabilities				(2,222)
Non-current operating lease liabilities				$ 10,697

Intangible assets, net and Go_3

Intangible assets, net and Goodwill (Details) € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Jul. 30, 2021USD ($)	Jul. 30, 2021EUR (€)
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Acquired licenses, net	$ 62,686	$ 3,361
Intangibles, net	62,686	3,361
Goodwill	$ 27,633	542
Weighted average remaining life	10 years 9 months 18 days
Capitalized expenditures related to milestone payments		2,200
Acquisition of Corlieve
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Provisional fair value of IPR&D intangible asset			$ 63,600	€ 53,600
Goodwill			$ 28,400	€ 23,919
Licenses
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Acquired licenses	$ 4,755	5,660
Less accumulated amortization	(2,827)	(2,299)
Acquired licenses, net	1,928	$ 3,361
Acquired research & development
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Acquired IPR&D Intangible Asset	$ 60,758

Intangible assets - Future amor

Intangible assets - Future amortization expense (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Estimated amortization expense for the next five years
Acquired licenses, net	$ 62,686	$ 3,361
Licenses
Estimated amortization expense for the next five years
2022	395
2023	133
2024	133
2025	133
2026	133
Thereafter	1,001
Acquired licenses, net	$ 1,928	$ 3,361

Intangible assets - Carrying am

Intangible assets - Carrying amount of Licenses (Details) - Licenses - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Intangible assets
Amortization of Intangible Assets	$ 1.2	$ 4.6	$ 0.6
Impairment expense related to licenses	$ 0	$ 0.3	$ 0

Accrued expenses and other cu_3

Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued expenses and other current liabilities
Accruals for goods received from and services provided by vendors-not yet billed	$ 13,012	$ 8,269
Personnel related accruals and liabilities	12,603	7,687
Accrued contract fulfillment costs and costs to obtain a contract	2,872
Contract liability		2,082
Total	$ 28,487	$ 18,038

Long-term debt (Details)

Long-term debt (Details) - USD ($) $ in Thousands	Apr. 01, 2024	Apr. 01, 2023	Dec. 15, 2021	Jan. 29, 2021	Dec. 06, 2018	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	May 31, 2020
Long-term Debt
Proceeds from loan increment, net of debt issuance costs						$ 64,067
Aggregate maturities of loan
Coupon interest payments and financing fees						35,600
2022						7,984
2023						10,580
2024						15,474
2025						101,549
Total						135,587
Prime Rate
Long-term Debt
Variable interest rate basis				8.25%
2016 Amended Facility \| Hercules \| Second Amended and Restated Loan and Security Agreement [Member]
Long-term Debt
Outstanding debt					$ 20,000
Proceed from drew down					$ 15,000
Interest rate (as a percent)					8.85%
Back-end fee (as a percent)					4.95%
Back-end fees due									$ 1,000
2016 Amended Facility \| Prime Rate \| Hercules \| Second Amended and Restated Loan and Security Agreement [Member]
Long-term Debt
Variable interest rate basis					8.85%
Discount rate (as a percent)					5.50%
2018 Amended Facility
Long-term Debt
Amortized cost net of discount and debt issuance costs							$ 35,900
2021 Amended Facility
Long-term Debt
Outstanding debt				$ 35,000
Proceed from drew down				$ 35,000
Interest rate (as a percent)				8.25%
Maximum borrowing capacity				$ 135,000
Additional unconditional borrowing capacity				$ 100,000
Back-end fees due			$ 2,500
Amortized cost net of discount and debt issuance costs						101,600
2021 Amended Facility \| Minimum
Long-term Debt
Back-end fee (as a percent)				1.65%
2021 Amended Facility \| Maximum
Long-term Debt
Back-end fee (as a percent)				6.85%
2021 Amended Facility \| Prime Rate
Long-term Debt
Discount rate (as a percent)				3.25%
2018 and 2021 Amended Facility
Long-term Debt
Outstanding debt			70,000	$ 70,000
Foreign currency loss						5,300		$ 700
Foreign currency gain							3,100
Restated Facility 2021
Long-term Debt
Outstanding debt			100,000			100,000
Proceed from drew down			$ 30,000
Interest rate (as a percent)			7.95%
Back-end fee (as a percent)			4.85%
Restated Facility 2021 \| Prime Rate
Long-term Debt
Variable interest rate basis			7.95%
Discount rate (as a percent)			3.25%
Venture debt loan facility \| 2018 Amended Facility
Long-term Debt
Assets pledged to secure facilities by directly or indirectly						809,200
Assets not being pledged to secure facilities by directly or indirectly						103,200
Venture debt loan facility \| 2018 and 2021 Amended Facility \| Hercules
Long-term Debt
Interest expense recorded						$ 7,200	$ 3,700	$ 3,700
Venture debt loan facility \| Restated Facility 2021
Long-term Debt
Minimum cash and cash equivalents in U.S. bank accounts						65.00%
Subsequent events. \| Venture debt loan facility \| Restated Facility 2021
Long-term Debt
Minimum cash and cash equivalents in U.S. bank accounts	30.00%	50.00%

Shareholder's equity (Details)

Shareholder's equity (Details) € / shares in Units, $ / shares in Units, $ in Thousands, € in Millions	Mar. 01, 2021USD ($)	Sep. 13, 2019USD ($)$ / sharesshares	Sep. 10, 2019$ / sharesshares	Apr. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2021USD ($)$ / €shares	Dec. 31, 2019USD ($)	Dec. 31, 2021EUR (€)€ / shares$ / €shares	Jun. 16, 2021shares	Dec. 31, 2020€ / shares	Dec. 31, 2020USD ($)shares
Authorized share capital					$ 4,500		€ 4
Common stock, additional shares authorized \| shares								20,000,000
Exchange rate (in USD per Euro) \| $ / €					1.13		1.13
Ordinary shares, authorized \| shares					80,000,000		80,000,000			60,000,000
Ordinary shares, par value (in euros per share) \| € / shares							€ 0.05		€ 0.05
Accumulated other comprehensive (loss) / income					$ (28,856)	$ (6,700)				$ 9,907
Aggregate offering price					29,564	242,674
Shares issued in connection with offering \| shares		733,695	4,891,305
Income tax benefit of past share issuance cost					3,047
Offering price per share of shares issued \| $ / shares		$ 46	$ 46
Gross Proceeds From Issuance Initial Public Offering		$ 258,800
Net proceeds from issuance of common stock		242,700				242,718
Expenses capitalized related to offering		$ 600
Proceeds from exercise of warrants						$ 500
Sales Agreement with SVB Leerink LLC
Percentage of gross proceeds	3.00%
Sales Agreement with SVB Leerink LLC \| Direct Incremental Labor
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs					$ 1,300
Sales Agreement with SVB Leerink LLC \| Ordinary shares
Shares issued in connection with offering \| shares				921,730
Share price (in dollars per share) \| $ / shares				$ 33.52
Net proceeds				$ 29,600
Sales Agreement with SVB Leerink LLC \| Maximum
Aggregate offering price	$ 200,000

Share-based compensation - Summ

Share-based compensation - Summary of share-based compensation expense and unrecognized costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2015
Share-based compensation
Share-based compensation expense	$ 25,607	$ 21,788	$ 17,468
Unrecognized compensation costs	$ 49,642
Weighted-average remaining period for recognition (in years)	2 years 5 months 12 days
2014 Plan
Share-based compensation
Increase in authorized shares	4,000,000			3,000,000	3,000,000	1,070,000
Authorized shares	12,601,471
2012 Plan
Share-based compensation
Outstanding of fully vested share options	14,000	14,000
Research and development expenses
Share-based compensation
Share-based compensation expense	$ 12,813	$ 11,965	8,029
Selling, general and administrative expense
Share-based compensation
Share-based compensation expense	12,794	9,823	9,439
Share options
Share-based compensation
Share-based compensation expense	12,477	$ 11,434	7,896
Unrecognized compensation costs	$ 29,513
Weighted-average remaining period for recognition (in years)	2 years 9 months 14 days
Share options \| 2014 Plan
Share-based compensation
Outstanding of fully vested share options	3,308,325	2,659,279
Restricted share units ("RSUs")
Share-based compensation
Share-based compensation expense	$ 11,347	$ 7,364	4,117
Unrecognized compensation costs	$ 19,348
Weighted-average remaining period for recognition (in years)	2 years
Performance Share Awards
Share-based compensation
Share-based compensation expense	$ 1,783	$ 2,990	$ 5,455
Unrecognized compensation costs	$ 781
Weighted-average remaining period for recognition (in years)	7 months 17 days

Share-based compensation - Opti

Share-based compensation - Option activity and weighted-average assumptions (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Weighted average exercise price
Total weighted average grant date fair value of options issued during the period (in $ millions)	$ 24,600
Proceeds from option sales during the period (in $ millions)	$ 2,700
Directors and Officers
Options
Granted (in shares)	312,704
Weighted average exercise price
Granted (in dollars per share)	$ 6.5
2014 Plan
Options
Thereof, outstanding and expected to vest at end of period (in shares)	1,521,500	1,116,874
Weighted average exercise price
Outstanding and expected to vest at end of the period (in dollars per share)	$ 22.52	$ 24.25
Vesting period (in years)	4 years
Weighted-average assumptions used to estimate fair value of share options granted during year
Expected volatility (as a percent)	75.00%	70.00%
Expected terms (in years)	10 years	10 years	10 years
Risk free interest rate, minimum (as a percent)	1.21%	0.76%	1.92%
Risk free interest rate, maximum (as a percent)	1.86%	1.44%	2.87%
Expected dividend (as a percent)	0.00%	0.00%	0.00%
2014 Plan \| Minimum
Weighted-average assumptions used to estimate fair value of share options granted during year
Expected volatility (as a percent)			70.00%
2014 Plan \| Maximum
Weighted-average assumptions used to estimate fair value of share options granted during year
Expected volatility (as a percent)			75.00%
2014 Plan \| Share options
Options
Outstanding at beginning of the period (in shares)	2,659,279
Granted (in shares)	1,174,893	653,852	647,526
Forfeited (in shares)	(258,718)
Expired (in shares)	(25,633)
Exercised (in shares)	(241,496)	(498,678)	(434,665)
Outstanding at end of the period (in shares)	3,308,325	2,659,279
Thereof, fully vested and exercisable at end of period (in shares)	1,786,825
Thereof, outstanding and expected to vest at end of period (in shares)	1,521,500	1,116,874
Weighted average exercise price
Outstanding at beginning of the period (in dollars per share)	$ 28.13
Granted (in dollars per share)	35.85
Forfeited (in dollars per share)	40.78
Expired (in dollars per share)	42.81
Exercised (in dollars per share)	10.98
Outstanding at end of period (in dollars per share)	31.02	$ 28.13
Thereof, fully vested and exercisable at end of period (in dollars per share)	24.47
Outstanding and expected to vest at end of the period (in dollars per share)	$ 38.71	$ 42.06
Weighted average remaining contractual life (in years)
Outstanding	7 years 18 days	7 years 2 months 4 days
Thereof, fully vested and exercisable at end of year	5 years 5 months 26 days
Outstanding and expected to vest at end of year	8 years 10 months 17 days
Aggregate intrinsic value
Outstanding (in dollars)	$ 8,660	$ 32,729
Thereof, fully vested and exercisable	8,640
Outstanding and expected to vest	20
Exercised (in dollars)	$ 5,046	$ 11,927	$ 17,700
Weighted average grant-date fair value
Vested (in shares)	507,503
Vested (in dollar per share)	$ 22.17
Forfeited (in dollar per share)	$ 23.60
2014 Plan \| Non-executive directors
Weighted average exercise price
Vesting period (in years)	1 year
2014 Plan \| One year from grant date
Weighted average exercise price
Vesting percentage per year	25.00%
Vesting period (in years)	1 year

Share-based compensation - RSU

Share-based compensation - RSU activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
2014 Plan
Other disclosure
Vesting period (in years)	4 years
2014 Plan \| Non-executive directors
Other disclosure
Vesting period (in years)	1 year
Restricted share units ("RSUs")
Number of shares
Non-vested at beginning of period (in shares)	467,344
Granted (in shares)	574,921
Vested (in shares)	(220,518)
Forfeited (in shares)	(111,130)
Non-vested at end of period (in shares)	710,617	467,344
Weighted average grant-date fair value
Non-vested at beginning of period (in dollars per share)	$ 43.56
Granted (in dollars per share)	36.14
Vested (in dollars per share)	40.56
Forfeited (in dollars per share)	40.98
Non-vested at end of period (in dollars per share)	$ 38.89	$ 43.56
Other disclosure
Total weighted average grant date fair value of RSUs granted during the period (in millions)	$ 20,800
Restricted share units ("RSUs") \| Non-executive directors
Other disclosure
Vesting period (in years)	1 year
Restricted share units ("RSUs") \| Directors and Officers
Number of shares
Granted (in shares)	167,230
Weighted average grant-date fair value
Granted (in dollars per share)	$ 6.1
Restricted share units ("RSUs") \| 2014 Plan
Number of shares
Granted (in shares)	574,921	376,799	198,504
Weighted average grant-date fair value
Granted (in dollars per share)	$ 36.14	$ 48.18	$ 38.63
Other disclosure
Total weighted average grant date fair value of RSUs granted during the period (in millions)	$ 8,063	$ 12,156	$ 10,152
Share options \| 2014 Plan
Weighted average grant-date fair value
Granted (in dollars per share)	$ 20.95	$ 28.08	$ 23.57
Minimum \| Restricted share units ("RSUs")
Other disclosure
Vesting period (in years)	1 year
Maximum \| Restricted share units ("RSUs")
Other disclosure
Vesting period (in years)	3 years

Share-based compensation - PSU

Share-based compensation - PSU activity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other disclosure
Service period	3 years	1 year
2014 Plan
Other disclosure
Vesting period (in years)			4 years
Performance Share Awards
Number of shares
Non-vested at beginning of period (in shares)			212,614
Granted (in shares)			555,600
Vested (in shares)			(132,368)
Forfeited (in shares)			(2,916)
Non-vested at end of period (in shares)	632,930		632,930	212,614
Weighted average grant-date fair value
Non-vested at beginning of period (in dollars per share)			$ 42.32
Granted (in dollars per share)			30.19
Vested (in dollars per share)			33.09
Forfeited (in dollars per share)			57.56
Non-vested at end of period (in dollars per share)	$ 33.54		$ 33.54	$ 42.32
Other disclosure
Total weighted average grant date fair value of RSUs granted during the period (in millions)			$ 16,800
Performance Share Awards \| 2014 Plan
Number of shares
Granted (in shares)			555,600	91,003	132,362
Weighted average grant-date fair value
Granted (in dollars per share)			$ 30.19	$ 57.56	$ 31.71
Other disclosure
Total weighted average grant date fair value of RSUs granted during the period (in millions)			$ 5,074	$ 21,852	$ 1,056
Share options \| 2014 Plan
Weighted average grant-date fair value
Granted (in dollars per share)			$ 20.95	$ 28.08	$ 23.57

Share-based compensation - Empl

Share-based compensation - Employee Share Purchase Plan - Narrative (Details) - ESPP - Employee Stock [Member] - shares	1 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based compensation
Ordinary shares available for issue	150,000	127,302
Discounted rate for purchase of shares	85.00%
Number of shares issued		4,724	6,181	9,202

Expenses by nature - Operating

Expenses by nature - Operating expenses excluding expenses presented in other expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Employee-related expenses	$ 96,161	$ 75,926	$ 59,130
Laboratory and development expenses	36,014	35,977	30,130
Legal and advisory expenses	24,767	17,370	11,297
Office and housing expenses	14,638	13,388	10,588
Other operating expenses	10,528	8,772	8,813
Depreciation and amortization expenses	7,299	10,648	6,669
Fair value loss - Corlieve contingent consideration	6,683
Patent and license expenses	3,748	2,899	1,654
Total	$ 199,838	$ 164,980	$ 128,281

Expenses by nature - Employee-r

Expenses by nature - Employee-related expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee-related expenses
Wages and salaries	$ 53,078	$ 40,919	$ 32,029
Share-based compensation expenses	25,635	21,831	17,533
Other employee expenses	4,570	2,635	1,392
Social security costs	4,496	4,068	2,727
Contractor expenses	3,170	2,423	2,464
Health insurance	3,161	2,271	1,933
Pension costs - defined contribution plans	2,051	1,779	1,052
Total	$ 96,161	$ 75,926	$ 59,130

Other income (Details)

Other income (Details) - USD ($) $ in Thousands	12 Months Ended
Other income (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Other Income	$ 12,306	$ 3,342	$ 1,888
Income from payments received from European authorities	5,300	1,900	700
Employee retention income	2,600	$ 0	$ 0
VectorY B.V
Schedule of Equity Method Investments [Line Items]
Settlement Income	$ 3,000
Number of shares acquired in conjunction with settlement agreement	69,899

Income taxes - Income (loss) be

Income taxes - Income (loss) before income tax (expense) benefit (Details) € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jul. 30, 2021USD ($)	Jul. 30, 2021EUR (€)
Loss before income taxes
Unrecognized Tax Benefits	$ 0	$ 0
Dutch operations	348,400	(130,493)	$ (111,820)
Income / (loss) before income tax (expense) / benefit	332,806	(141,443)	(124,201)
Current tax expense
Total current tax (expense)	(7)
Deferred tax benefit / (expense)
Dutch operations	(3,047)
Total deferred tax (expense) / benefit	(3,210)	16,419
Income tax (expense) / benefit	(3,217)	16,419
Acquisition of Corlieve
Loss before income taxes
Deferred tax liability, net				$ 14,200	€ 11,900
U.S. operations
Loss before income taxes
Loss before income tax benefit / (expense)	(12,737)	(10,950)	$ (12,381)
Deferred tax benefit / (expense)
Deferred tax (expense) / benefit	(771)	$ 16,419
Other
Loss before income taxes
Loss before income tax benefit / (expense)	(2,857)
Current tax expense
Current tax (expense)	(7)
Deferred tax benefit / (expense)
Deferred tax (expense) / benefit	$ 608

Income taxes - Tax rate reconci

Income taxes - Tax rate reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Tax rate reconciliation
Income / (loss) before income tax (expense) / benefit for the period		$ 332,806	$ (141,443)	$ (124,201)
Expected income tax (expense) / benefit at the tax rate enacted in the Netherlands (25%)		(83,201)	35,361	31,050
Non-deductible expenses		(9,182)	(5,041)	(4,972)
Other net change in valuation allowance		88,857	(30,568)	(25,583)
Difference in tax rates between the Netherlands and the U.S. as well as other foreign countries		309	247	(495)
Release of valuation allowance related to expected future taxable income of U.S. operations		88,858	(30,568)	$ (25,583)
Income tax (expense) / benefit		$ (3,217)	$ 16,419
Enacted tax rate	25.80%	25.00%	25.00%	25.00%
Non-deductible expenses, Share-based compensation		$ 6,700	$ 5,800	$ 4,400
Fair value loss on contingent consideration		$ 2,000	0	$ 0
U.S. operations
Tax rate reconciliation
Release of valuation allowance related to expected future taxable income of U.S. operations			$ 16,419
Enacted tax rate		21.00%

Income taxes - Significant comp

Income taxes - Significant components of deferred taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 71,917	$ 158,614
Operating lease liabilities	9,300	9,515
Intangible assets	2,039	1,702
Accrued expenses and other current liabilities	1,312	1,118
Property, plant and equipment	971	1,072
Inventory	148
Research and development tax credit carryforwards	105
Interest carryforwards		1,597
Derivative financial instrument		661
Total deferred tax assets	85,792	174,279
Less valuation allowance	(60,289)	(150,113)	$ (109,856)	$ (85,100)
Deferred tax assets, net of valuation allowance	25,503	24,166
Deferred tax liabilities:
Acquired IPR&D Intangible Asset (see Note 3, "Corlieve transaction")	(15,189)
Operating lease right-of-use assets	(7,493)	(7,702)
Other current assets and receivables	(87)	(45)
Deferred tax liability	(22,769)	(7,747)
Net deferred tax asset	$ 2,734	$ 16,419

Income taxes - Changes in valua

Income taxes - Changes in valuation allowance (Details) - USD ($) $ in Thousands	Jun. 24, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Opening balance		$ 60,289	$ 150,113	$ 109,856	$ 85,100
Changes recorded in the statement of operations			(88,858)	30,568	25,583
Increase related to 2021, 2020 and 2019 Dutch tax reforms			1,897	18,287	4,059
Valuation allowance assumed in Corlieve acquisition			545
Other changes including currency translation adjustments			(3,408)	7,821	(4,886)
Ending balance			60,289	150,113	$ 109,856
Amount of valuation allowance for deferred tax assets within contributed capital as it relates to follow on offering costs.			$ 4,500	$ 7,700
Enacted tax rate		25.80%	25.00%	25.00%	25.00%
U.S. operations
Changes recorded in the statement of operations				$ (16,419)
Release of valuation allowance related to expected current year and future periods recorded in profit and loss				$ (16,419)
Enacted tax rate			21.00%
CSL Behring collaboration
Upfront cash to receive upon the closing of the agreement	$ 450,000

Income taxes - Effective Tax Ra

Income taxes - Effective Tax Rate (Details) - USD ($) $ in Thousands	Jan. 01, 2022	Jul. 30, 2021	May 06, 2021	Jan. 01, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net operating loss carryforwards utilization							$ 1,200	$ 800
Enacted tax rate					25.80%	25.00%	25.00%	25.00%
Income tax benefit of past share issuance cost						$ 3,047
Revenue						$ 524,002	$ 37,514	$ 7,281
Operating loss carryforwards period (in years)				6 years		9 years
U.S. operations
Effective income tax rate						27.32%
Enacted tax rate						21.00%
France
Effective income tax rate	25.00%					26.50%
Operating Loss Carryforwards, Not Subject to Expiration						$ 9,100
CSL Behring collaboration
Revenue			$ 462,400			$ 517,400	$ 0	$ 0
Acquisition of Corlieve
Enacted tax rate		25.00%

Income taxes - Tax losses expir

Income taxes - Tax losses expiring (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Tax loss carry-forwards
Tax loss carry-forwards	$ 228.5	$ 588.2	$ 414
2019
Tax loss carry-forwards
Loss expiring			$ 20.7
U.S. operations \| 2021
Tax loss carry-forwards
Tax loss carry-forwards	$ 39.1

Basic and diluted earnings pe_3

Basic and diluted earnings per share - Ordinary share (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net income / (loss) attributable to ordinary shares	$ 329,589	$ (125,024)	$ (124,201)
Weighted-average number of ordinary shares outstanding - basic	45,986,467	44,466,365	39,999,450
Weighted-average number of ordinary shares outstanding - diluted	46,840,972	44,466,365	39,999,450
Stock options \| Previous plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based payment arrangements	746,044
Stock options \| ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based payment arrangements	1,299
Non-vested RSUs and PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based payment arrangements	107,162

Basic and diluted earnings pe_4

Basic and diluted earnings per share (Details) - shares	12 Months Ended
Basic and diluted earnings per share (Details) - shares	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Basic and diluted earnings per share
Total potential dilutive ordinary shares	3,814,508	3,353,797	12,440,841
BMS Warrants \| Bristol Myers Squibb
Basic and diluted earnings per share
Total potential dilutive ordinary shares			8,893,000
Stock options \| Previous plan
Basic and diluted earnings per share
Total potential dilutive ordinary shares	2,576,281	2,673,279	2,697,104
Stock options \| ESPP
Basic and diluted earnings per share
Total potential dilutive ordinary shares	1,842	560	485
Non-vested RSUs and PSUs
Basic and diluted earnings per share
Total potential dilutive ordinary shares	1,236,385	679,958	850,252

Related party transaction (Deta

Related party transaction (Details) - Jul. 30, 2021 € in Millions, $ in Millions	EUR (€)	USD ($)
Acquisition of Corlieve
Related Party Transaction [Line Items]
Business acquisition consideration in the form of equity issued	€ 44.9	$ 53.3